TOPIRAMATE- topiramate tablet NuCare Pharmaceuticals, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TOPIRAMATE tablets, safely and effectively. See full prescribing information for TOPIRAMATE tablets, USP. TOPIRAMATE tablets USP, for oral Use.

Initial U.S. Approval: 1996

- Warnings and Precautions, Visual Field Defects (5.2) 01/2014

- INICLATIONS AND USAGE Informate tables USP is an antegiate (AED) agent dataset for: Monotherapy epilepsy, histal monotherapy in patients = 2 years of age with partial onset or primary generalized forult-coinc sessures (11). Unburrayly or values and pediatric patients (2 to 15 years of age) with partial onset secures or primary generalized foruit-coinc setures, and in patients = 2 years of age with secures associated with Lemond-Castaut syndrome (LS) (1 z).

DOSAGE AND ADMINISTRATION See DOSAGE AND ADMINISTRATION, Epilepsy: Monotherapy and Adjunctive Therapy Use for additional details _____

	Initial Dose	Titration	Recommended Dose
Epilepsy monotherapy:_ children 2to<10years_(2.1)	25mg/day administered nightly for the first week	The dosage should betitratedover5-7 weeks	Daily doses in two divided doses based on weight(Table2)
Epllepsy monotherapy: adults and pediatric patients≥10years [2.1]	divided doses	The dosage should be increased weekly by increments of 50mg for the first 4 weeks then100mgfor weeks 5to6.	400 mg/day in two divided doses
Epilepsy adjunctive therapy:adults.with partial onset seizures or LGS(2.1)	25to50mg/day	The dosage should be increased weekly to an effective dose by incrementsof25to50mg.	200-400 mg/day in two divided doses
Epilepsy adjunctive therapy: adults with primary generalized tonic- clonic seizures (2.1)	25to50mg/day	The dosage should be increased weekly to an effective dose by incrementsof25to50mg.	400 mg/day in two divided doses
Epilepsy adjunctive therapy: pediatric Patients with partial onset sejures, primary generalized tonic-clonic sejures or LGS(186 2.1)	of1to3mg/kg/day)	The dosage should beincreasedat1-or 2-weekintervalsby incrementsof1to3 mg/kg/day(administered in two divided doses).Dose titration should be guided by clinical outcome.	5to9mg/kg/day in two divided doses

Tablets: 25 mg, 50 mg, 100 mg, and 200 mg (3)

None (4)

- CONTRANDICATIONS

 None (4)

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANDICATIONS

 CONTRANTS
 CONTRANDICATIONS

 CONTRANTS
 CONTRANDICATIONS

 CONTRANTS
 CONTRANTS

ADVERSE REACTIONS The most common (>10% more frequent than placebo or low-dose topiramate in monotherapy) adverse reactions at recommended dosing in adult and pediatric controlled, epilepsy clinical trials were paresthesia, anorea, weight decrease, speech disorder related speech problem, fatgibue, dizziness, sparesthesia, anorea, weight decrease, speech disorder related speech problem, fatgibue, dizziness, puresuresa, anorexa, wegnt decrease, speech disorder related speech problem, fatigue, dizziness, somolence, nervousness, psychomotor isowing, abnormal vision, and fever. (6) To report SUSPECTED ADVERSE REACTIONS, contact Cipia Ltd, at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch DRUG INTERACTIONS Summary of antiepileptic drug (AED) interactions with topiramate tablets (7.1)

AED Co-administered	AED Concentration	Topiramate Concentration
Phenytoin	NCor25%increase ^a	48%decrease
Carbamazepine(CBZ)	NC	40%decrease
CBZepoxide ^b	NC	NE
Valproic acid	11%decrease	14%decrease
Phenobarbital	NC	NE
Primidone	NC	NE
Lamotrigine	NCatTPM dosesupto400 mg/day	13%decrease

One contracted/sec: Decreased contracted/sec efficacy and brossed breakthrough bleeding should be considered, esculption takes growther than 500 mg/sky (173)
 Medformin is contraindicated with metabolic acidosis, an effect of topianante tables (7.4)
 Lithium levels should be monitored when co-administered with high-dose topianante tables (7.5)
 Other carbonic anhydrose inhibitors: Monitor the patient for the appearance or vorsening of metabolic acidosis (7.6)

- USE IN SPECIFIC POPULATIONS
 USE IN SPECIFIC POPULATIONS
 In an impairment: In remaily impaired patients (creatinine clearance less than 70 mtLmin/L,73 m⁻),
 non-haid of the aduit does is recommended (1,4)
 Programary: Increased risk of cell time patients and the providable (0,5) Cosage adjustment is
 necessary to avoid rapid drops in topiamate plasma concentration during hemodialysis (1,6)
 Pregnancy: Increased risk of cell time aduit pairong tables (1,6).
 Nursing mothers: Caulton should be exercised when administered to a nursing mother (1,8)
 Geriatric uses Dosage adjustment may be necessary to rederiv with impaired renal function (1,6).

See 17 for Medication Guide.

Revised: 1/2015

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1 INDICATIONS AND USAGE
1 2 Adjunctive Therapy Epilepsy
2 OSAGE AND ADMINISTRATION
2.1 Epilepsy
2.4 Patients (average 56 Years and Over)
2.5 Gerärtric Patents (Ages 65 Years and Over)
2.6 Patients Undergoing Hemodialysis
2.7 Patients with Heipatic Decesse
2.7 Patients with Heipatic Decesse
3.7 Patients with Heipatic Decesse
3.7 Patients with Heipatic Decesse
3.7 Patients with Heipatic Decesse
3.8 OUTRANDICATIONS
3.1 Acute Myopia and Secondary Angle Closure Glaucoma
5.2 Visual Field Defects
5.3 Oligohidrosis and Phycerthermia
5.4 Metabole Acidosis
5.5 Succial Behavior and Ideation
5.7 Fedial Toxicity
5.8 Withdrawal of Anticejkeptic Drugs (AEDS)
5.9 Sudden Unexplained Death in Epilepsy (SUDEP)
5.10 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic
Acid (VPA) Use)
5.11 Hypothermia With Concomitant Valproic Acid (VPA) Use
5.12 Hypothermia Behaviora Y Tests
5.4 Addustionermia With Concomitant Valproic Acid (VPA) Use
5.13 Hypothermia Behaviora Y Tests
5.4 Decesse
5.4 Adjustment of Dose in Renal Falure
5.15 Decreased Hegatic Function
5.16 Monitoring: Laboratory Tests
6.4 Decessed Hegatic Function
5.2 Possident Altoria Suboratory Tests
6.2 Possimetiated of ther Experience

- 6.1 Clinical Trial Experience 6.2 Postmarketing and Other Experience DRUG INTERACTIONS
- 7.1 Antiepileptic Drugs 7.2 CNS Depressants 7.3 Oral Contraceptive 7.4 Metformin

- 7.5 Lithium 7.6 Other Carbonic Anhydrase Inhibitors 8 USE IN SPECIFIC POPULATIONS
- 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use

- 8.5 Geriatric Use 8.6 Race and Gender Effect 8.7 Renal Impairment 8.8 Patients Undergoing Hemodialysis 8.9 Women of Childbearing Potential 10 OVERDOSAGE 11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY

13 MORCLINICAL TOXICOLOGY
 13.1 Carcinogenesis, and Impairment of Fertility
 14.1 Monotherapy Epileopy Controlled Trial
 14.1 Monotherapy Epileopy Controlled Trial
 14.2 Adjunctive Therapy Epileopy Controlled Trials
 16 HOW Supplied
 16.1 How Supplied
 16.2 Storage and Handling
 * Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Monotherapy Epilepsy

Topiranate tables USP are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic secures. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials [see Clinical Studies (14.1)].

1.2 Adjunctive Therapy Epilepsy

Topiramate tablets USP are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures or primary generalized tonic-cionic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome [see Clinical Studies (14.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Epilepsy

It is not necessary to monitor topiramate plasma concentrations to optimize topiramate therapy.

Because of the bitter taste, tablets should not be broken.

Topiramate tablets USP can be taken without regard to meals.

Monotherapy Use

Adults and Pediatric Patients 10 Years and Older The recommended does for topiamate monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doeses. Approximately 55% of patients randomized to 400 mg/day achieved this maximal does an the monotherapy controlled trial; the mean does achieved in the trial was 275 mg/day. The does should be achieved by thration according to the following schedule (Table 12):

Table 1: Monotherapy Titration Schedule for Adults and Pediatric Patients 10 years and older

	Morning Dose	Evening Dose
Week 1	25 mg	25 mg
Week 2	50 mg	50 mg
Week 3	75 mg	75 mg
Week 4	100 mg	100 mg
Week 5	150 mg	150 mg
Week 6	200 mg	200 mg

Children Ages 2 to <10 Years

Dosing of topiramate as initial monotherapy in children 2 to < 10 years of age with partial onset or primary generalized tonic-clonic seizures was based on a pharmacometric bridging approach [see Clinical Studies (14.1)]

pharmacometric bridging approach (see Lunical studies (14.1)) Dosing in patients 2 to <10 years is based on weight. During the thration period, the initial dose of topiramate should be 25 mg/day administered nightly for the first week. Based upon toterability, the dosage can be increased to 50 mg/day (25 mg twice daily) in the second week. Dosage can be increased by 25-50 mg/day each subsequent week as tolerated. Thration to the minimum maintenance dose should be attempted over 5-7 weeks of the total itration period. Based upon tolerability and secure control, additional taction to a higher dose (top to the maximum maintenance) cos) can be attempted at 25-50 mg/day and the secure to the maximum maintenance dose (and be attempted over 5-7) maintenance dose for each range of body weight (Table 2).

Table 2: Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to <10 Years

Weight (kg) Total Daily Dose (mg/day) * Total Daily Dose (mg/day) Г

weight (kg)	Minimum Maintenance Dose	Maximum Maintenance Dose
Up to 11	150	250
12 - 22	200	300
23 - 31	200	350
32 - 38	250	350
Greater than 38	250	400
*Administered in two equ	ally divided doses	

Adjunctive Therapy Use

Adults 17 Years of Age and Over - Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

Consistences of the minor-based as a significant of the second se

In the study of primary generalized tonic-clonic seizures, the initial titration rate was sower than in previous studies; the assigned dose was reached at the end of 8 weeks [see Clinical Studies (14.1)]

Pediatric Patients Ages 2 – 16 Years – Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome

Construction control to control to the second secon 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome.

In the study of primary generalized tonic-clonic seizures, the initial titration rate was slower than in previous studies; the assigned dose of 6 mg/kg/day was reached at the end of 8 weeks [see *Clinical Studies* (14.1)].

2.4 Patients with Renal Impairment

In renally impaired subjects (creatinine clearance less than 70 mL/min/1.73 m ²), one-half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.

Dosage adjustment may be indicated in the elderly patient when impaired renal function (creatinine clearance rate <70 mL/min/1.73 m2) is evident [see Clinical Pharmacology (12.3)].

2.6 Patients Undergoing Hemodialysis

A or Automics Underground reindungsis Topiramate is cleared by hemodulaysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fail below that required to maintain an anti-secure effect. To avoid rapid drops in topiramate plasma concentration during hemodulysis, a supplemental dose of invincion of dialysis period. 21 the clearance ratio of the dialysis system below (a) the effective renal clearance of topiramate in the patient being dialyzed.

2.7 Patients with Hepatic Disease

In hepatically impaired patients, topiramate plasma concentrations may be increased. The mechanism is not well understood.

Topiramate tablets USP are available in the following strengths and colors

25 mg, White colored, circular, biconvex film-coated tablets, debossed with "122" on one side and "C" on the other side 50 mg, Light orange colored, circular, biconvex, film-coated tablets, debossed with "123' on one side and "C" on the other side.

100 mg, Orange colored, circular, biconvex, film-coated tablets, debossed with "124" on one side and "Cipla" on the other side.

200 mg, Pink colored, capsule shaped, biconvex, film-coated tablets, debossed with "125" on one side and "Cipla" on other side.

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 Acute Myopia and Secondary Angle Closure Glaucoma

5.1 Acute Myopia and Secondary Angle Closure Glaucoma A syndrome constitup of acute myopia associated with secondary angle closure glaucoma has been reported in patients receiving topiramate. Symptoms include acute onset of decreased visual acuty and/or ocuter pain. Ophthamologic findings can include myopia, anterior chamber shallowing, ocular hyperemik (redness), and increased intraocuter pressure. Mydraise may or may not be present. This syndrome may be associated with supracillary effusion resulting in anterior displacement of the lens and risk, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating topiramate therapy. In contrast to primary narrow angle glaucoma, which is repair anate. Provides or agrice the present may be associated with supracillary effusion resulting in anterior displacement of the lens and risk, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating topiramate therapy. In contrast to primary narrow angle glaucoma, which is contrast the ludgement of the treatung physician. Other measures, in conjunction with discontinuation of topiramate, may be hepful.

Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent vision loss.

5.2 Visual Field Defects

Visual field defects (independent of elevated intraocular pressure) have been reported in clinical trais, and in post marketing experience in patients receiving topiramate. In clinical trais, most of these events were reversible after topiramate discontinuation. If visual problems occur at any time during topiramate treatment, consideration should be given to discontinuing the drug.

5.3 Oligohidrosis and Hyperthermia

Objointirosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with topiramate use. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.

reported after exposure to elevated environmental temperatures. The majority of the reports have been in pediatric patients, relatents, especially pediatric patients, treated with topramate should be monitored cisely for evidence of decreased eventing and increased body temperature, especially in hoit vestmer. Caution should be used when topiramate is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.

5.4 Metabolic Acidosis

5.4 Metabolic Acidosis
Hyperchloremic, non-anion gap, metabolic acidosis (i.e., decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory akabsis) is associated with topiramate treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such extrabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced metabolic acidosis biccurs early in treatment abhough cases can occur at any time description of the second second second in the post-marketing period. Generally, topiramate-induced of a frequit at chaly doses of 400 mg in adults and at approximately 6 mg/rigiday in pediatric patients;) rarely, patients can experience severe decrements to values below 10 mGqL. Conditions or therapies that predispose patients to acidosis (such as renal disease, severe expiratory disorders, status epilepticus, diarriens, ketogenic diet, or specific drugs) may be additive to the bicarbonate lowaring effects of topiramate. Some manifestations of acute or chronic metabolic acidosis may include

Some manifestations of acute or chronic metabolic acidosis may include hyperventibion, nonspecific symptoms such as fatigue and anorexia, or more severe sequebe including cardiac arrhythmiss or stupor. Chronic, untreated metabolic acidosis may horease the risk for nephrotibhasis or nephrocacinosis, and may also result in osteomalacia (referred to as rickets in pediatric patients) and/or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of Topiramate on growth and bone-related sequelese has not been systematically investigated in long-term, placebo-controlled trials. Long-term, open-able treatment of infarits/Todies', with intractable partial epidesy, for up to 1 year, short metaccomprometables and the second of the second Epilepsy

Adult patients

Adult patients in adults, the incidence of persistent treatment-emergent decreases in serum bicarbonate (levels of <20 mEq.l, at two consecutive visits or at the final visit) in controlled clinical trials for adjunctive treatment of pelipsy was 32% for 400 mg/day, and 1% for piacebo. Metabolic acidosis has been observed at doses as low as 50 mg/day. The indicance of a markedly abnormally low serum bicarbonate (i.e. absolute value <11 mEq.l, and >5 mEq.l decrease from pretreatment) in the adjunctive therapy trials was 3% for 400 mg/day, and 0% for placebo. The ncidence of persistent treatment-emergent decreases in serum bicarbonate in adult patients (>216 years of treatment-emergent decreases in serum bicarbonate in adult patients (>216 years of dig) in the eglepsy controlled Cinkal trial for monotherapy was 14% for 50 mg/day (i.e., absolute value <17 mEq.l, and >5 mEgl. decrease from pretreatment) in this trial for adults was 3% for 50 mg/day and 6% for dox 00 mg/day. Serum bicarbonate levels have not been systematically evalueted at daily doses greater than 400 mg/day.

Pediatric patients

Pediatric patients In mergent decreases it serum bicarbonate in pikecho-controlled trials for adjunctive treastment of Lennox-Gastaut syndhome or refractory partial conset seizures was 67% for topriamate(at approximate) fi mg/kg/day), and 10% for pikecho. The incidence of a markedy abnormaly to wermu bicarbonate (i.e., absolute value <17 mEqL and >5 mEqL decrease from pretreatment) in these trials was 11% for topiramate and 0% for pikecho. Cassaut set is a pixetistic acidosis have been reported in patients as young as 5 months old, especially at daiy doses above 5 mg/kg/day. Although not approved for use in patients under 2 years of age with partial onset seizures, a controlled trial that examined this population revealed that topiramate produced a metabolic acidosis that is notably greater in magnitude than that beserved in controlled trials in older children and adults. The mean treatment difference (25 metabolic acidosis (idening by a serum bicarbonate <20 mEqL) was 0% for pikecbo, 3% for 5 mg/kg/day, 50% for 15 mg/kg/day, and 45% for 25 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, and 45% for 25 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, and 45% for 25 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, and 45% for 25 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50% for 15 mg/kg/day, and 5% for 25 mg/kg/day, 50% for 15 mg/kg/day, 50

Im 2.5 improved process in spectra ropulations (a.4).
In pediatric painting (6 to 15 years of age), the incidence of persistent treatment-emergent decreases in serum bicarbonate in the epilepsy controlled clinical trial for monotherapy was 9% for 50 mg/day and 25% for 400 mg/day. The incidence of a markedly abnormally two serum bicarbonate (i.e., absolute value <17 mEgL and >5 mEgL decrease from pretreatment) in this trial was 1% for 50 mg/day and 6% for 400 mg/day.

Measurement of Serum Bicarbonate in Epilepsy Patients

Measurement of baseline and periodic serum bicarbonate during topiramate treatment is recommended. If metabolic acidosis develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent acidosis, alkali treatment should be considered.

5.5 Suicidal Behavior and Ideation

Antieplieptic drugs (AEDs), including topiramate, increase the risk of suicidal thoughts o behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled anayses of 199 piecebo-controlled clinical trais (mono- and adjunctive here any) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Realtive Risk 1, 9, 6% c. (12, 2, 2) of suicidal thinking or behavior compared to patients randomized to placebo. In these traits, which had a median treatment duration of 12 weeks. The estimated indicate rate of suicidal behavior or ideation among 27, 863 AED-treated patients was 0.43%, compared to 0,24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every S30 patients treated. There were forus vuickies in drug-treated patients in the triais and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect

on suicide.

The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed

The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk vapiles to al AEDs used for any indication. The risk idd not vary substantially by age (5 to 100 years) in the clinical trials analyzed.

Table 4 shows absolute and relative risk by indication for all evaluated AEDs

Table 4: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis

Indication	Placebo Patients with Events per 1000 Patients	Drug Patients with Events per 1000 Patients	Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients	Risk Difference: Additional Drug Patients with Events per 1000 Patients
Epilepsy	1.0	3.4	3.5	2.4
Psychiatric	5.7	8.5	1.5	2.9
Other	1.0	1.8	1.9	0.9
Total	2.4	4.3	1.8	1.9
		•		

The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing topiramate or any other AED must balance the risk of Anyone considering prescribing topiramate or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated liness. Epilepsy and many othe linesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the liness being treated.

These being utexts. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

5.6 Cognitive/Neuropsychiatric Adverse Reaction

Adverse reactions most often associated with the use of topiramate were related to the Adverse reactions most often associated with the use of topic anade were readed to on certral nervous system and were observed in epilepsy populations. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g., confusion, psychomotor solwing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-inding difficulties); 2) Psychiatrichebavioral disturbances (e.g., depression or mood problems); and 3) Somnolence or fatigue.

Adult Patients

Cognitive-Related Dysfunction

The majority of cognitive-related adverse reactions were mild to moderate in severity, and they frequently occurred in isolation. Rapid thration rate and higher initial dose were associated with higher incidences of these reactions. Many of these reactions contributed to withdrawal from treatment [see Adverse Reactions (6)].

contributed to withdrawal from treatment [see Adverse Reactions (6)]. In the add-on epilepsy controlled trials (using rapid titration such as 100-200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse reactions was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 55% for 600 and 1.000 mg/day, and 14% for placebo. These doss-related adverse reactions began with a similar frequency in the titration or in the maintenance phase, although in some patients the events began during titration and persisted into the maintenance phase. Some patients who experienced one or more cognitive-related adverse reactions in the tratation phase had a dos-related recurrence of these reactions in the maintenance phase.

In the monotherapy epilepsy controlled trial, the proportion of patients who experienced one or more cognitive-related adverse reactions was 19% for topiramate50 mg/day and one or more cognitiv 26% for 400 mg/day

Psychiatric/Behavioral Disturbances

Psychiatric/behavioral disturbances (depression or mood) were dose-related for epilepsy population [see Warnings and Precautions (5.5)].

Somnolence/Fatique

Sominone and fatigue were the adverse reactions most frequently reported during clinical trials of topiramate for adjunctive epilepsy. For the adjunctive epilepsy population, the incidence of somnoince durin durin differ substantially between 200 mg/day and 1.000 mg/day, but the incidence of fatigue was dose-related and increased at dosages above 400 mg/day. For the monotherapy epilepsy population in the 50 mg/day and 400 mg/day groups, the incidence of somnoince was dose-related (9% for the 50 mg/day group and 15% for the 400 mg/day group) and the incidence of fatigue was comparable in both treatment groups (14% each).

Additional nonspecific CNS events commonly observed with topiramate in the add-on epilepsy population included dizziness or ataxia.

Pediatric Patients

Pediatric Patients In double-bild adjunctive therapy and monotherapy epilepsy clinical studies, the incidences of cognitive/neuropsychiatric adverse reactions in pediatric patients were generally lower than observed in adults. These reactions included psychomotor slowing, difficulty with concentration/attention, speech disorders/related speech problems, and language problems. The most frequently reported neuropsychiatric reactions in pediatric patients during adjunctive therapy double-bild studies were somnolence and fatigue. The most frequently reported neuropsychiatric reactions in pediatric patients during adjunctive therapy double-bild studies were somnolence and fatigue heradache, dizziness, amorexia, and somnolence.

No patients discontinued treatment due to any adverse reactions in the adjunctive epilepsy double-bind trials. In the monotherapy epilepsy double-bind trial, 1 pediatric patient (2%) in the 50 mg/day group and 7 pediatric patients (12%) in the 400 mg/day group discontinued treatment due to any adverse reactions. The most common adverse reaction associated with discontinuation of theragy was difficulty with concentration/attention; all occurred in the 400 mg/day group.

5.7 Fetal Toxicity

Topiramate can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate *in utero* have an increased risk for cleft lip and/or cleft palate (oral clefts). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural maformations, including craniofacial defects, and reduced fetal weights occurred in offspring [see Use in Specific Populations (8.1)].

Onspiring [see Use in specific Populations (a.1)]. Consider the benefits and the risks of top/amate when administering this drug in women of childbearing potential, particularly when top/amate is considered for a condition not usually associated with permanent injury or death [see Use in Specific Populations (8.9) and Patient Counseling Information (17)]. Top/amate should be used during pregnancy only if the potential heart the potential risk. If this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1) and (8.9)].

5.8 Withdrawal of Antiepileptic Drugs (AEDs)

In patients with or without a history of seizures or epilepsy, antiepileptic drugs, including topiramate, should be gradually withdrawn to minimze the potential for seizures or increased seizure frequency [see Clinical Studies (14)]. In stuations where rapid withdrawal of Topiramate is medically required, appropriate monitoring is recommended.

5.9 Sudden Unexplained Death in Epilepsy (SUDEP)

During the course of premarketing development of topiramate tablets, 10 sudden and unexplained deaths were recorded among a cohort of treated patients (2796 subject years of exposure). This represents an incidence of 0.0035 deaths per patient year. Athough this rate exceeds that expected in a heathy population matched for age and esex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving topiramate tablets (ranging from 0.0005 for the general population of patients with epilepsy. to .003 for a chical trial population similar to that in the topiramate tablets program, to 0.005 for patients with refractory epilepsy).

5.10 Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use)

Hyperammonemia/Encephalopathy Without Concomitant Valproic Acid (VPA) Trajemantinuenenaerineapinaabaatur minouu Controllentiin vaatus keisti terrai Topiramate treatment has produced hyperammonia in a ciliati investigational program in very young pediatric patients (1 to 24 months) who were treated with adjunctive topiramate for partial ionset epilepsy (1% for placebo, 10% for 5 mg/kg/day, 0% for 15 mg/kg/day, 9% for 25 mg/kg/day). In some patients, ammonia was marked increased (250% above upper limit of normal). The hyperammonia associated with topiramate treatment occurred with and without encephiaipathy in placebo-controlled traje and in open-label, externisto in trai of inflants with refractionry epilepsy. Doseuses and in an open-adve, exception in and or induct window with fer actory (papely). Dose-related hyper-momenia was observed in the extension trial in pediatric patients up to 2 years old. Clinical symptoms of hyperarminonemic encephalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. Topiramate tablet is not approved as adjunctive treatment of partial onset seizures in pediatric patients less than 2 years old.

Hyperammonemia with and without encephalopathy has also been observed in post-

marketing reports in patients who were taking topiramate without concomitant valproic acid (VPA).

Hyperammonemia/Encephalopathy With Concomitant Valproic Acid (VPA)

Ingreatinitatienterinateinetarium y man contentinatien variautus redutterinatienterinateinetarium variante and varianteria enterinatienter

Although topiramate tablet is not indicated for use in infants/toddlers (1-24 months), Topiramate with concomitant VPA clearly produced a dose-related increase in the Topramate with concomitant VPA clearly produced a dose-related increase in the incidence of treatment-emergent hyperammonemia (above the upper limit of normal, 0% for placebo, 12% for 5 mg/kg/day, 7% for 15 mg/kg/day, 17% for 25 mg/kg/day) in an investigational program. Markedly increased, dose-related hyperammonemia (0% for placebo and 5 mg/kg/day, 7% for 15 mg/kg/day, 8% for 25 mg/kg/day) also occurred in these infants/roddlers. Dose-related hyperammonemia (above the in a long-term extension trial in these very young, pediatric patients [see Use h Specific Populations (5.4)].

Hyperammonemia with and without encephalopathy has also been observed in post-marketing reports in patients taking topiramate with VPA.

The hyperammonemia associated with Topiramate treatment appears to be more common when topiramate is used concomitantly with VPA.

Monitoring for Hyperammonemia

Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity be at an increased risk for hyperanmonemia with or without encephalopathy. Altho not studied, Toparamate treatment or an interaction of concomitant topiramate and valprok acid treatment may exacerbate existing defects or unmask deficiencies in susceptible persons.

In patients who develop unexplained lethargy, vomiting, or changes in mental status associated with any topiramate treatment, hyperammonemic encephalopathy should be considered and an ammonia level should be measured.

5.11 Kidnev Stones

5.11 Kidney Stones A total of 32/2066 (1.5%) of adults exposed to topiramate during its adjunctive epileps therapy development reported the occurrence of kidney stones, an incidence about 2 4 times greater than expected in a similar, untreaded population. In the double-bind monotherapy epilepsy study, a total of 4/319 (1.3%) of adults exposed to topiramate reported the occurrence of kidney stones. As a the general population, the incidence stone formation among topiramate-treated patients was higher in men. Köney stones have abo been reported in pediatir patients taking topiramate for epilepsy.

During long-term (up to 1 year) topiamate treatment in an open-label extension study of 284 pediatric patients 1-24 months old with epilepsy. 7% developed kitney or bladde stones that were diagnosed clinically or by sonogram. Topiamate tablet is not approve for pediatric patients less than 2 years old [see Use h Specific Populations (8.4)].

run peuauric patients less than 2 years old [see Use in Specific Populations (8.4)]. An explanation for the association of top/amate tablets and kindney stones may le in the fact that top/amate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor, factoria anhydrase inhibitor, factoria and any chrate acetacalamile, or dichtoprintenaide) can promote stone formation by Precautions (5.4). The concommant use of top/amate tablets with any other drug producing metabolic acidosis, or potentially in patients on a ketogenic diet, may create a physiological environment that increases the risk of kidney stone formation, and should therefore be avoided.

Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation.

5.12 Hypothermia with Concomitant Valproic Acid (VPA) Use

5.12 Hypotherma with Concentiant Vapproc Acid (VPA) Use Hypothermia, defined as an unithentional drop in body core temperature to <35°C (95°F). has been reported in association with topiramate use with concomtant valproic acid (VPA) both in conjunction with thyperammonemia and in the absence of hyperammonemia. This adverse reaction in patients using concomtant topiramate and valproate can occur after starting topfarmate transmit or after increasing the daily dose of topiramate (see Drug) Interactions (7.11). Consideration should be given to stopping topiramate convelocities in patients who develop hypotherma, which mays and significant alterations in other major organ systems such as the cardiovascular and respiratory stretures. Chical management and assessment should include examination of blood ammonia levels. and

5.13 Paresthesia

Any paresthesia usually inging of the extremities), an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of topiamate tablets. Paresthesia was more frequently reported in the monotherapy epilepsy trials and migrahe prophylaxis trials than in the adjunctive therapy epilepsy trials. In the majority of instances, paresthesia did not lead to treatment discontinuation.

5.14 Adjustment of Dose in Renal Failure

The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dosage adjustment may be required in patients with reduced renal function [see Dosage and Administration (2.4)].

5.15 Decreased Hepatic Function

In hepatically impaired patients, topiramate tablets should be administered with caution as the clearance of topiramate may be decreased [see Dosage and Administration (2.7)]

5.16 Monitoring: Laboratory Tests

Topiramate treatment was associated with changes in several clinical laboratory analytes in randomized, double-blind, placebo-controlled studies.

Topriamate treatment causes non-anion gap, hyperchloremic metabolic acidosis manifested by a decrease in serum bicarbonate and an increase in serum chioride. Measurement of baseline and periodic serum bicarbonate during topriamate tablets treatment is recommended [see Warnings and Precautions (5.4)].

Topiramate tablets treatment with or without concomitant valproic acid (VPA) can cause hyperammonemia with or without encephalopathy [see Warnings and Precautions (hypera 5.10)]

Epilepsy

Controlled trials of adjunctive topiramate treatment of adults for partial onset seizures showed an increased incidence of markedly decreased serum phosphorus (5% topiramate, 2% placebo), markedly increased serum akaine phosphatase (3% topiramate, 1% placebo), and decreased serum potassium (0.4 % topiramate, 0.1 % placebo).

Changes in several clinical laboratory analytes (i.e., increased creatinne, BUN, alkaline phosphatase, total protein, total eosinophi count, and decreased potassium) have been observed in a clinical investigational program in very young (<2 years) pediatric patients who were treated with adjunctive topiramate for partial onset sebures *[see Use in Specific Populations (8.4)]*.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

Acute Myopia and Secondary Angle Closure [see Warnings and Precautions (5.1)1

Visual Field Defects [see Warnings and Precautions (5.2)] Oligohidrosis and Hyperthermia [see Warnings and Precautions (5.3)] Metabolic Acidosis [see Warnings and Precautions (5.4)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)] Cognitive/Neuropsychiatric Adverse Reactions [see Warnings and Precautions (

5.6)]

Fetal Toxicity [see Warnings and Precautions (5.7) and Use in Specific ions (8.1)] Populat Withdrawal of Antiepileptic Drugs (AEDs) [see Warnings and Precautions (5.8)]

Sudden Unexplained Death in Epilepsy (SUDEP) [see Warnings and Precautions (5.9)]

Hyperammonemia and Encephalopathy (Without and With Concomitant Valproic Acid [VPA] Use) [see Warnings and Precautions (5.10)] Kidney Stones [see Warnings and Precautions (5.11)]

Hypothermia with Concomitant Valproic Acid (VPA) Use [see Warnings and Precautions (5.12)]

Paresthesia [see Warnings and Precautions (5.13)]

The data described in the following sections were obtained using topiramate tablets

6.1 Clinical Trial Experience

Monotherapy Epilepsy

Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to the incidence or adverse reactions in the clinical trials of another drug, and may not reflect the incidence of adverse reactions observed in practice.

Increased Risk for Bleeding

Topiramate tablets treatment is associated with an increased risk for bleeding. In a

puexe analysis of placebo-controlled studies of approved and unapproved indications, bleeding was more frequently reported as an adverse event for topiramate tablets than for placebo (4.5% versus 3.0% in aduit patients, and 4.4% versus 2.3% in prediatric patients). In this analysis, the incidence of serious bleeding events for topiramate tablets and placebo was 0.3% versus 0.2% for aduit patients, and 0.4% versus 0% for pediatric patients. pooled

Adverse bleeding reactions reported with topiramate tablets ranged from mild epistaxis, ecchymosis, and increased menstrual bleeding to life-threatening hemorrhages. In patients with serious bleeding events, conditions that increased the risk for bleeding were often present, or patients were often taking drugs that cause thrombocytopenia (other antippleptic drugs) or affect platelet function or coagulation (e.g., aspirin, norsteroid an ini-information yourgs, sective seriotionin reuptale hibbors, or warfarin

or other anticoagulants).

Monotherapy Epilepsy

Adults ≥16 Years

The adverse reactions in the controlled trial that occurred most commonly in adults in the 400 mg/day topiramate group and at a rate higher (\geq 5 %) than in the 50 mg/day group were: paresthesia, weight decrease, anorexia, somnolence, and difficulty with memory (see Table 5).

Approximately 21% of the 159 adult patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. The most common (a 2 % more frequent than bw-dose 50 mg/day topiramate) adverse reactions causing discontinuation in this trial were difficulty with memory, fatgue, asthenà, isnomia, somnolence, and paresthesia.

Pediatric Patients 6 to <16 Years of Age

Feadul: Failens 0.0 4.10 feas of age The adverse reactions in the controlled trial that occurred most commonly in pediatric patients in the 400 mg/day topiramate tablets group and at a rate higher (\ge 5%) than in the 50 mg/day group were fever, weight decrease, mood problems, cognitive problems, infection, flushing, and paresthesia (see Table 5). Table 5 also presents the incidence of adverse reactions occurring in at least 2% of adult and pediatric patients treated with 400 mg/day topiramate tablets and occurring with greater incidence than 50 mg/day topiramate tablets.

top animate course. Approximate justice of the two products of two products of the two products of two products of two products of the two products of two products of the two products of two products of the two products of two products o

Table 5: Incidence of Treatment-Emergent Adverse Reactions in Monotherapy Epilepsy Where the Rate Was at Least 2% in Any Topiramate Tablets Group and the Rate in the 400 mg/day Topiramate Tablets Group Was Greater Than the Rate in the 50 mg/day Topiramate Tablets Group for Adults (±16 Years) and Pediatric (6 to <16 Years) Patients in Study TOPMAX-EMM-106

	Age Group				
	Pediatric		Adult		
	(6 to <1		Ad (Age ≥1		
		Tablets Dai	ly Dosage Gr	oup (mg/day)	
Body System	50 (N=74)	400 (N=77)	50 (N=160)	400 (N=159)	
Adverse Reaction	(N=74) %*	(N=77) %*	(N=100) %*	(N=159) %*	
Body as a Whole - General Disorde					
Asthenia	0	3	4	6	
Chest pain			1	2	
Fever	1	12			
Leg pain Central & Peripheral Nervous Syste	Discute		2	3	
Ataxia	in Disorders		3	4	
Dizziness			13	14	
Hypertonia			0	3	
Hypoesthesia			4	5	
Muscle contractions involuntary	0	3			
Paresthesia	3	12	21	40	
Vertigo Gastro-Intestinal System Disorders	0	3			
Constipation			1	4	
Diarrhea	8	9	-		
Gastritis			0	3	
Gastroesophageal reflux			1	2	
Dry mouth			1	3	
Liver and Biliary System Disorders					
Gamma-GT increased Metabolic and Nutritional Disorders			1	3	
Weight decrease	7	17	6	17	
Platelet, Bleeding & Clotting Disord	, lers		Ŭ,		
Epistaxis	0	4			
Psychiatric Disorders					
Anorexia			4	14	
Anxiety			4	6	
Cognitive problems Confusion	1	6	1	4	
Depression	0	3	7	9	
Difficulty with concentration/attention	7	10	7	8	
Difficulty with memory	1	3	6	11	
Insomnia			8	9	
Libido decreased			0	3	
Mood problems	1	8	2	5	
Personality disorder(behavior problems) Psychomotor slowing	0	3	3	5	
Somnolence			10	15	
Red Blood Cell Disorders			10	15	
Anemia	1	3			
Reproductive Disorders, Female [†]					
Intermenstrual Bleeding	0	3			
Vaginal Hemorrhage			0	3	
Resistance Mechanism Disorders	3	8	2	3	
Infection Infection viral	3	6	6	8	
Respiratory System Disorders	2	Ū	Ŭ	0	
Bronchitis	1	5	3	4	
Dyspnea			1	2	
Rhinitis	5	6	2	4	
Sinusitis	1 16	4			
Upper respiratory tract infection Skin and Appendages Disorders	16	18			
Acne			2	3	
Alopecia	1	4	3	4	
Pruritus			1	4	
Rash	3	4	1	4	
Special Senses Other, Disorders					
Taste perversion			3	5	
Urinary System Disorders Cystitis			1	3	
Dysuria			0	2	
Micturition frequency	0	3	0	2	
Renal calculus			0	3	
Urinary incontinence	1	3			
Urinary tract infection			1	2	
Vascular (Extracardiac) Disorders		1			

Unitary trade nitection in 1 2 Vascular (Extracardiac) Disorders 0 5 Filtshing 0 5 Percentages calculated with the number of subjects in each group as denominator 7 N with Female Reproductive Disorders - Incidence calculated relative to the number of females; Pediatric TMV 50 mg n=33, 400 mg n=33, 400 mg n=30, 400 m

Adjunctive Therapy Epilepsy

The most commonly observed adverse reactions associated with the use of topiramate tablets at dosages of 200 to 400 mg/day (recommended dose range) in controlled trials in adults with partial anosts eizeures, primary generalized tonic-choins seizures, or Lennox-Gastaut syndrome, that were seen at an incidence higher (a 5%) than in the placebo group were : somnolence, weight decrease, anorexia, diziness, ataxia, speech disorders and related speech problems, language problems, psychomotor slowing, confusion, abnormal vision, difficulty with memory, paresthesis, diplopia, nervousness, and asthenia (see Table 6). Dose-related adverse reactions at dosages of 200 to 1,000

mg/day are shown in Table 8.

The most commonly observed adverse reactions associated with the use of topiramate tablets at dosages of 5 to 9 mg/kg/day in controlled trials in pediatric patients with partial onset seizures, primary generalized tonk-choic seizures, or Lennox-Gastaut Syndrome, that were seen at an incidence higher (z 5%) than in the placebo group were : fatigue, somnolence, anorexia, envouenses, difficulty with concentration/attention, difficulty with memory, aggressive reaction, and weight decrease (see Table 9). Table 9 also presents the incidence of adverse reactions occurring in at least 1% of pediatric patients treated with topiramate tablets and occurring with greater incidence than placebo.

ucences wan uppr emate tablets and occurring with greater incidence than placebo. In controlled chinal tribis in adults, 11% of patients receiving topiramate tablets 200 to 400 mg/day as adjunctive therapy discontinued due to adverse reactions. This rate appeared to increase at dosages above 400 mg/day. Adverse reactions associated with discontinuing therapy included sommolence, durzeness, anixely, difficulty with concentration or attention, fatigue, and paresthesia and increased at dosages above 400 mg/day at 5 to 9 mg/kg/day in controlled clinical trials discontinued due to adverse reactions.

reactions. Approximately 28% of the 1757 adults with epilepsy who received topiramate tablets at dosages of 200 to 1,600 mg/day in clinical studies discontinued treatment because of advance of the second studies of the second studies of the second studies of the memory (3.2%), fattigue (3.2%), contrusin (6.1%), sourcelence (3.2%), difficulty with memory (3.2%), fattigue (3.2%), contrusin (6.1%), sourcelence (3.2%), difficulty with concentration/attention (2.9%), anorexia (2.7%), depression (2.6%), distributes (2.6%). Approximately 11% of the 310 pediatric patients who received topiramate tablets at dosages up to 30 mg/kg/day discontinued due to adverse reactions. Adverse reactions associated with discontinuing therapy included aggravated convulsions (2.3%), difficulty, and sommolence (1.3%), and source (1.3%), and source (1.3%), personality (1.3%), and sommolence (1.3%).

Incidence in Eplepsy Controlled Clinical Trails – Adjunctive Therapy – Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, and Lennox-Gastaut Syndrome Table 6 lists treatment-emergent adverse reactions that occurred in at least 1% of adults treated with 200 to 400 mg/day topiramate tablets in controlled trials that were numerically more common at this dose than in the patients treated with placebo. In general, most patients who experienced adverse reactions during the first eight weeks of these trials no longer experienced them by their last visit. Table 9 lists treatmentemergent adverse reactions that occurred in at least 1% of pediatric patients treated with 5 to 9 mg/dx topiramate tablets in controlled trials that were numerically more common than in patients treated with placebo.

common than in patients treated with placebo. The prescriber should be aware that these data were obtained when topiramate tablets was added to concurrent antiepileptic drug therapy and cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cled frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. In specific on these frequences, however, does provide the prescribing physician with a becation incidences in the population studied.

Other Adverse Reactions Observed During Double-Blind Epilepsy Adjunctive Therapy Trials

Other adverse reactions that occurred in more than 1% of adults treated with 200 to 400 mg of topiramate in placebo-controlled epilepsy trials but with equal or greater frequency in the placebo group were headchet, injury, anxikty, rash, pain, convulsions aggravated, couphing, fever, diarrhea, vomiting, muscle weakness, insomnia, personality disorder, dysmeorrhea, upper respiratory tract infection, and eye pain.

Table 6: Incidence of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On Epilepsy Trials in Adults *1 Where Incidence Was >1% in Any Topiramate Tablets Group and Greater Than the Rate in Placebo-Treated Patients

		L	
Parks Contains (Disaster	200-400	osage (mg/day)
Body System/	Placebo (N=291)	200-400 (N=183)	
Adverse Reaction [‡]	(N=291)	(N=183)	(N=414)
Body as a Whole - General Disorders	13	15	30
Asthenia	13	6	30
Astrienia Rock poin	4	5	3
Back pain Chest pain	4	4	2
nfluenza-like symptoms	2	4	4
	2	2	4
.eg pain Hot flushes	1	2	4
Allergy	1	2	3
Edema	1	2	1
Body odor	0	1	0
Digors	0	1	<1
Rigors C entral & Peripheral Nervous System Dizziness Ataxia	Disorders	-	~1
Dizziness	15	25	32
Atavia	7	16	14
Speech disorders/Related speech problems	2	13	11
Paresthesia	4	11	19
Vystagmus	7	10	11
Fremor	6	9	9
anguage problems	1	6	10
anguage problems Coordination abnormal Hypoesthesia Sait abnormal	2	4	4
dvpoesthesia	1	2	1
Sait abnormal	1	3	2
Muscle contractions involuntary	1	2	2
Stupor	0	2	1
/ertigo	1	1	2
Gastro-Intestinal System Disorders	1	1	2
Vausea	8	10	12
Dyspepsia	6	7	6
Abdominal nain	4	6	7
Constipation Gastroenteritis		4	3
Sectroenteritic	1	2	1
Dry mouth	1	2	4
Singulatic	<1	1	1
Gingivitis GI disorder	<1	1	0
Hearing and Vestibular Disorders	~1		U
Hearing decreased	1	2	1
Metabolic and Nutritional Disorders	-	2	1
Weight decrease	3	9	13
Muscle-Skeletal System Disorders	-	-	
Myalgia Skeletal pain	1	2	2
Skeletal pain	0	1	0
Platelet, Bleeding, & Clotting Disorde	rs		
Epistaxis Psychiatric Disorders	1	2	1
Psychiatric Disorders			
Somnolence	12	29	28
Vervousness	6	16	19
sychomotor slowing	2	13	21
Difficulty with memory	3	12	14
Anorexia	4	10	12
Confusion	5	11	14
Anorexía Confusion Depression	5	5	13
Difficulty with concentration/attention	2	6	14
Mood problems	2	4	9
	2	3	3
Aggressive reaction	2	3	3
Agressive reaction motional lability Cognitive problems .bido decreased	1	3	3
Cognitive problems	1	3	3
ibido decreased	1	2	<1
Apathy	1	1	3
Depersonalization	1	1	2
Reproductive Disorders, Female			
Breast pain	2	4	0
Amenorrhea	1	2	2
Menorrhagia	0	2	1
Menstrual disorder	1	2	1
Reproductive Disorders, Male			
Prostatic disorder	<1	2	0
Resistance Mechanism Disorders			
nfection	1	2	1
nfection viral	1	2	<1
Moniliasis	<1	1	0
Respiratory System Disorders			
Pharyngitis	2	6	3
Rhinitis	6	7	6
Sinusitis	4	5	6
Dyspnea	1	1	2
Skin and Appendages Disorders			
Skin disorder Sweating increased	<1	2	1
Sweating increased	<1	1	<1
Rash erythematous	<1	1	<1

0	2	4
1	2	<1
1	2	3
1	1	2
<1	2	1
0	1	<1
2	13	10
5	10	10
1	2	1
	1 1 1 <1	1 2 1 2 1 1 <1

Detectoppenion Patients in best add-on/ adjunctive triels were needing 1 to 2 concomitant antepieptic drugs in Patients in present the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category. Adverse reactions reported by a least 1% of patients in the topiramete tablets 200–400 mg/day group and more common than in the placebo group are listed in this table.

Incidence in Study 119 - Add-On Therapy- Adults with Partial Onset Seizures Study 119 was randomized, double-bind, add-on/adjunctive, placebo-controlled, parallel group study with 3 treatment arms: 1) placebo; 2) topramate tablets 200 mg/day with a 25 mg/day starting dose, increased by 25 mg/day each week for 8 weeks until the 200 mg/day maintenance dose was reached; and 3) topramate tablets 200 mg/day with a 50 mg/day starting dose, increased by 50 mg/day each week for 4 weeks until the 200 mg/day maintenance dose was reached; Ad Jatients were maintained on concomitant carbonaceptiew with or without amother concomitant antipleptief drug.

Concommant carbamacephere with or without another concommant anticipate caruption of the most commonly observed adverse reactions associated with the use of topiamate tablets that were seen at an incidence higher (> 5%) than in the placebo group were paresthesia, nervousness, somolonec, difficulty with concentrationAntention, and fatigue (see Table 7). Because these topiamate tablets theatment difference incidence (for plantate tablets) the discover protein this study were markedly by werthen these reported in the previous epilepsy studies, they cannot be directly compared with data obtained in other studies

Table 7: Incidence of Treatment-Emergent Adverse Reactions in Study 119 *, † Where Incidence Was ≥ 2% in the Topiramate Tablets Group and Greater Than the Rate in Placebo-Treated Patients

Adverse Reaction [‡] (N= Body as a Whole-General Disorders Tafigue d'Antonio Crest pain Cardiovascular Disorders, General Hypertension Central & Peripheral Nervous System Dis Paresthesia d'Antonio Central & Peripheral Nervous System Dis	I 9 I 2 orders 2 2 9 I 7 2 3 3 2
Body as a Whole-General Disorders Fatgue Chest pain Cardiovascular Disorders, General Hypertension Central & Peripheral Nervous System Dis Paresthesia	4 9 1 2 0 2 orders 2 2 9 4 7 2 3 0 2
Fatigue 4 Chest pain 2 Cardiovascular Disorders, General Hypertension 0 Central & Peripheral Nervous System Dis Paresthesia 2	2 orders 2 9 4 7 2 3 0 2 3 0 2 3 0 2 3 0 2 2 3 0 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 3 2 3 2 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3
Chest pain Cardiovascular Disorders, General Hypertension Central & Peripheral Nervous System Dis Paresthesia 2	2 orders 2 9 4 7 2 3 0 2 3 0 2 3 0 2 3 0 2 2 3 0 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 3 2 3 2 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3
Cardiovascular Disorders, General Hypertension (Central & Peripheral Nervous System Dis Paresthesia	2 orders 2 4 7 2 3 0 2 2 3 0 2 2 3 0 2 2 3 0 2 2 3 0 2 2 3 0 2 2 3 0 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 3 2 2 2 3 2 2 2 3 2 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2
Hypertension (Central & Peripheral Nervous System Dis Paresthesia 2	orders 9 2 9 4 7 2 3 0 2
Central & Peripheral Nervous System Dis Paresthesia	orders 9 2 9 4 7 2 3 0 2
Central & Peripheral Nervous System Dis Paresthesia	2 9 4 7 2 3 0 2 0 2 0 2
	4 7 2 3 0 2 0 2
Dizziness	2 3) 2) 2) 2
	2 0 2 2
Tremor	2
Hypoesthesia (
Leg cramps (2
Language problems (
Gastro-Intestinal System Disorders	
	3 5
Constipation () 4
Diarrhea	1 2
Dyspepsia (2
Dry mouth (2
Hearing and Vestibular Disorders	
Tinnitus (2
Metabolic and Nutritional Disorders	
	4 8
Psychiatric Disorders	
Somnolence	9 15
Anorexia	7 9
	2 9
	5
Insomnia	3 4
Difficulty with memory	1 2
Aggressive reaction (2
Respiratory System Disorders	
) 4
Urinary System Disorders	
	2
Vision Disorders	
Diplopia (2
Vision abnormal ()	2

 Vision abnormal
 0
 2

 Patients in these add-on/adjunctive trials were receiving 1 to 2 concomitant anticipileptic drugs in addition to topiramate tablets or placebo.
 10
 2 concomitant anticipileptic drugs in Addition to topiramate tablets or placebo.

 Values represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.
 Adverse reaction category.

 Valves reported more than one adverse reaction. Junction than in the placebo group are listed in this table.
 200 mg/day group

Table 8: Incidence (%) of Dose-Related Adverse Reactions From Placebo-Controlled, Add-On Trials in Adults With Partial Onset Seizures *

	Topiramate	a Tablets D	osage (mg/day)
Placebo	200	400	600 - 1,000
(N = 216)	(N = 45)	(N = 68)	(N = 414)
13	11	12	30
7	13	18	19
1	7	9	14
4	9	10	14
6	9	7	13
4	4	6	12
<1	2	9	10
6	2	3	10
2	0	6	9
3	4	9	13
	Placebo (N = 216) 13 7 1 4 6 4 <1	Placebo 200 (N = 216) (N = 45) 13 11 7 13 1 7 4 9 6 9 4 4 <1	(N = 216) (N = 45) (N = 68) 13 11 12 7 13 18 1 7 9 4 9 10 6 9 7 4 4 6 <1

response studies were not conducted for other adult indications or for pediatric indications.

Table 9: Incidence (%) of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On Epilepsy Trials in Pediatric Patients (Ages 2 - 16 Years) -, i (Reactions That Occurred in at Least 1% of Topiamate Tablets-Treated Patients and Occurred More Frequently in Topiamate Tablets -Treated Than Placebo-Treated Patients)

Body System/	Placebo	Topiramate
Adverse Reaction	(N=101)	(N=98)
Body as a Whole - General Disorders		
Fatique	5	16
Injury	13	14
Allergic reaction	1	2
Back pain	0	1
Pallor	0	1
Cardiovascular Disorders, General		
Hypertension	0	1
Central & Peripheral Nervous System	Disorders	
Gait abnormal	5	8
Ataxia	2	6
Hyperkinesia	4	5
Dizziness	2	4
Speech disorders/Related speech problems	2	4
Hyporeflexia	0	2
Convulsions grand mal	0	1
Fecal incontinence	0	1
Paresthesia	0	1
Gastro-Intestinal System Disorders		
Nausea	5	6
Saliva increased	4	6
Constipation	4	5
Gastroenteritis	2	3
Dysphagia	0	1
Flatulence	0	1
Gastroesophageal reflux	0	1
Glossitis	0	1
Gum hyperplasia	0	1
Heart Rate and Rhythm Disorders		
Bradycardia	0	1
Metabolic and Nutritional Disorders		
Weight decrease	1	9
Thirst	1	2

Hypoglycemia	0	1
Weight increase	0	1
Platelet, Bleeding, & Clotting Disorders	5	
Purpura	4	8
Epistaxis	1	4
Hematoma	0	1
Prothrombin increased	0	1
Thrombocytopenia	0	1
Psychiatric Disorders		
Somnolence	16	26
Anorexia	15	24
Nervousness	7	14
Personality disorder (behavior problems)	9	11
Difficulty with concentration/attention	2	10
Aggressive reaction	4	9
nsomnia	7	8
Difficulty with memory	0	5
Confusion	3	4
Psychomotor slowing	2	3
Appetite increased	0	1
Neurosis	0	1
Reproductive Disorders, Female		
Leukorrhea	0	2
Resistance Mechanism Disorders		-
Infection viral	3	7
Respiratory System Disorders	-	
Pneumonia	1	5
Respiratory disorder	0	1
Skin and Appendages Disorders		-
Skin disorder	2	3
Alopecia	1	2
Dermatitis	0	2
Hypertrichosis	1	2
Rash erythematous	0	2
Eczema	0	1
Seborrhea	0	1
Skin discoloration	0	1
Urinary System Disorders	v	1 -
Urinary incontinence	2	4
Nocturia	0	1
Vision Disorders	v	1 1
Eye abnormality	1	2
Vision abnormal	1	2
Diplopia	0	1
Lacrimation abnormal	0	1
	U	1 1
Myopia	0	1

 O
 O
 J
 addition to topiramate tablets or placebo. 2 otic drugs in

Values represent the percentage of patients reporting a given adverse reaction. Patients may have reported more than one adverse reaction during the study and can be included in more than one adverse reaction category.

Other Adverse Reactions Observed During All Epilepsy Clinical Trials

Other Adverse Reactions Observed During All Epilepsy Clinical Trials Topiramate tables has been administered to 2246 adults and 427 pediatric patients with epilepsy during all clinical studies, only some of which were placebo-controlled. During these studies, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of reactions were grouped into a smaller number of standardized categories using modified WH0ART dictionary terminology. The frequencies presented represent the proportion of patients who experimened a reaction of the type cited on at least one occasion while receiving therviewing tables or text, those on general to be informable, and those an explicationably associated with the use of the drug.

Reactions are classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent occurring in at least 1/100 patients; infrequent occurring in 1/100 to 1/1000 patients; rare occurring in fewer than 1/1000 patients.

Autonomic Nervous System Disorders: Infrequent: vasodilation Body as a Whole: Frequent: syncope. Infrequent: abdomen enlarged. Rare: alcohol

Cardiovascular Disorders, General: Infrequent: hypotension, postural hypotension, angina pectoris

angua peccolas. Central & Peripheral Nervous System Disorders: Infrequent: neuropathy, apraxia, hyperesthesia, dyskinesia, dysphonia, scotoma, ptosis, dystonia, visual field defect, encephalopathy, EEG abnormal. Rare: upper motor neuron lesion, cerebelar syndrome, tongue paralysis.

Gastrointestinal System Disorders: Infrequent: hemorrhoids, stomatitis, melena, gastritis, esophagitis. Rare: tongue edema. Heart Rate and Rhythm Disorders: Infrequent: AV block.

Liver and Biliary System Disorders: Infrequent: SGPT increased, SGOT increased. Metabolic and Nutritional Disorders: Infrequent: dehydration, hypocalcemia, hyperlipemia, hyperglycemia, xerophthalmia, diabetes mellitus. Rare: hypernatremia, hyponatremia, hypocholesterolemia, creatinine increased.

Musculoskeletal System Disorders: Frequent: arthralgia. Infrequent: arthrosis. Neoplasms: Infrequent: thrombocythemia. Rare: polycythemia.

Platelet, Bleeding, and Clotting Disorders: Infrequent: gingival bleeding, pulmonary embolism.

Psychiatric Disorders: Frequent: impotence, hallucination, psychosis, suicide attempt. Infrequent: euphoria, paranoid reaction, delusion, paranoia, delirium, abnormal dreaming. Rare: libido increased, manic reaction.

Red Blood Cell Disorders: Frequent: anemia. Rare: marrow depression, pancytopenia Reproductive Disorders, Male: Infrequent: ejaculation disorder, breast discharge.

Skin and Appendages Disorders: Infrequent: urticaria, photosensitivity reaction, abnormal hair texture. Rare: chloasma. Special Senses Other, Disorders: Infrequent: taste loss, parosmia.

Urinary System Disorders: Infrequent: urinary retention, face edema, renal pain, albuminuria, polyuria, olguria.

Vascular (Extracardiac) Disorders: Infrequent: flushing, deep vein thrombosis, phlebitis, Rare: vasospasm

Vision Disorders: Frequent: conjunctivitis. Infrequent: abnormal accommodation, photophobia, strabismus. Rare: mydriasis, iritis.

White Cell and Reticuloendothelial System Disorders: Infrequent: lymphadenopathy, eosinophilia, lymphopenia, granulocytopenia. Rare: lymphocytosis.

6.2 Postmarketing and Other Experience

In addition to the adverse experiences reported during clinical testing of topiramate tablets, the following adverse experiences have been reported worldwide in patients receiving topiramate tablets post-approval.

These adverse experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: bulkous skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermai necrolysis), hepatic failure (including fatalities), hepatits, maculopathy, pancreatils, and pemphigus.

7 DRUG INTERACTIONS

/ DRUG INTERACTIONS In vitro studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2Q9, CYP2D6, CYP2E1, and CYP3A4A Siozymes. In vitro studies indicate that topiramate is a mill inhibor of CYP2C19 and a mild inducer of CYP3A4. Drug interactions with some antiepilepitc drugs, CNS depressants and oral contraceptives are described here. For other drug interactions, please refer to *Clinical Pharmacology (12.3)*.

7.1 Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. Concombant administration of phenytoin or catharnazepine with topiramate devices. A standard of the patient of the standard pharmacology (12.3). Upprante given alone (see Clinical Pharmacology (12.3).

Concomitant administration of valprok acid and topiarnate tablets has been associated with hyperammonenia with and without encephalopathy. Concomitant administration of topiarnate tablets with valprok acid has also been associated with hypothermik (with and without hyperammonenia) in patients who have tolerated either drug alone. It may be prudent to examine blood armonal levels in patients in whom the onset of hypothermik has been reported (see Warnings and Precautions (5.10), (5.12) or Clinical Pharmacology (12.5)).

Concomitant administration of topiramate tablets and akohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramete to cause CNS depression, as well as other cognitive and/or neuropsychiatirc adverse reactions, topiramate tablets should be used with extreme caution if used in combinatio with akohol and other CNS depressants.

7.3 Oral Contraceptives

Exposure to ethinyl estradiol was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when topiramate tablets wa 400, and 800 mg/day 118%, 21%, and 30%, respectively) when topiramate tablets was given as adjunctive therapy in patients taking vaprole cad. However, norethindrone exposure was not significantly affected. In another pharmacokinetic interaction study in healthy volunteers with a concomitanity administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), topiramate tablets, given in the absence of other medications at doese of 50 to 200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking combination oral contraceptive products with hopiramate tablets. Patients taking estrogen-containing contraceptives should be asked to report any change in their bleeding patients. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding [see *Clinical Pharmacology* (12.3)].

7.4 Metformin

Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated [see Clinical Pharmacology (12.3)].

7.5 Lithium

In patients, lithium levels were unaffected during treatment with topiramate at doses of 200 mg/day, however, there was an observed increase in systemic exposure of lithium (27% for Cmax and 26% for AUC) following topiramate doses of up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose topiramate tablets [see Clinical Pharmacology (12.3)].

7.6 Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic Concommant use or opin antace, a car domin, an input ase minitority, who any outries carbonic anitydrase inhibitor (e.g., zonismidia, sactazolomitik, or dichloriphenamide) may increase the severity of metabolic actiosis and may also increase the risk of kidney stone formation. Therefore, If topfamatic tablets is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of metabolic actiosis (see Clinica) Pharmacology (2.3)).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category D Isee Warnings and Precautions 5.7

<u>Pregnancy Category D</u> [see Warnings and Precautions 5.7] Topiramate tablets can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate *in utero* have an increased risk for cleft ip and/or cleft palate (oral clefts). When multiple species of pregnant animals received topicating tablets (and clefts). When multiple species of offspring. Topiramate tablets should be used during pregnancy only if the potential benefit outweighs the potential risk. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.9)]. Pregnancy Registry

Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnacy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patie can call the tol-free number 1-888-233-2334. Information about the North American Drug Pregnancy Registry can be found at http://www.massgemeatorg/aed/. Human Data

Dutiani Data Data from the NAAED Pregnancy Registry (425 prospective topiramate monotherapy-exposed pregnancies) indicate an increased risk of oral clefts in infants exposed during the first trinsector of pregnancy. The prevalence of oral clefts among topiramate-exposed infants was 1.2% compared to a prevalence of 0.39% for infants exposed to a reference AED. In infants of mothers without eighpsy or treatment with other AEDs. The prevalence was 0.12%, For comparison, the Centers for Disease Control and Prevention (CCD) reviewed available data on oral clefts in the United States and found a similar background rate of 0.17%. sed to a

background rate of oral clefts in topiramate-exposed pregnancies in the NAAED Pregnancy Registry was 9.6 (95% Confidence Interval[C] 4.0 – 23.0) as compared to the risk in a background population of untreated women. The UK Deplesy and Pregnancy Register reported a similarly increased prevalence of oral clefts of 3.2% among infants exposed to topiramate monotherapy. The observed rate of rai clefts was 16 times higher than the background rate in the UK, which is approximately 0.2%.

was 16 times higher than the background rate in the UK, which is approximately 0.2%. Topiramate tablets treatment can cause metabolic acidosis *(see Warnings and Precautions (5.4)*). The effect of topiramate-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the feus' ability to totareal tables. The studies of the studies and the studies of the studies

Animal Data

Animal Data Topiramate has demonstrated selective developmental toxicity, including teratogenicity, in multiple animal species at clinically relevant doses. When oral doses of 20, 100, or 500 mg/kg were administered to pregnant mice during the period of organogenesis, the incidence of fetal malformations (primarity cranoficial id detex) was increased at all doses. The low dose is approximately 0.2 times the recommended human dose (RHD) 400 mg/dg an amg/m² fabas. Fetal body weights and skeletal ossification were reduced at 500 mg/kg in conjunction with decreased maternal body weight gain. In rat studies (oral doses of 20, 100, and 500 mg/kg or 0.2, 2.5, 30, and 400 mg/kg), the frequency of limb malformations (etcrodactyly, micromelia, and amela) was increased among the offspring of dams treated with 400 mg/kg (10 times the RHD on a mg/m² basis) or greater during the organogenesis period of pregnancy. Embryotoxicity reduced fetal body weights, increased india bove, and maternal body weight gain was reduced during treatment with 100 mg/kg or greater. In explicit fullies (20, 60, and 100 mg/kg or greater.

was reduced outing treatment with 100 mg/kg of 0 greater. In rabbt studies (20, 60, and 180 mg/kg of 10, 35, and 120 mg/kg or ally during organogenesis), embryoffetal mortality was increased at 35 mg/kg (2 times the RHD on a mg/m² Abasis) or greater, and teratogenic effects (primarily rib and vertebral maformations) were observed at 120 mg/kg (6 times the RHD on a mg/m² Abasis). Evidence of maternal toxickly (decreased body weight gain, clinical signs, and/or mortality) was seen at 35 mg/kg and above.

Intransity) was seen at 35 mg/kg and adove. When femaler arts were treated during the latter part of gestation and throughout lactation (0.2, 4, 20, and 100 mg/kg or 2, 20, and 200 mg/kg), offspring exhibited decreased viability and delayed physical development at 200 mg/kg (5 times the RHD or a mg/m 2 basis) and reductions in preand/or postweaning body weight gain at 2 mg/kg (0.5 times the RHD on a mg/m 2 basis) and show. Maternal toxicity (decreased body weight gain, clinical signs) was evident at 100 mg/kg or greater. ea BHD on

In a rat embryoffelal development study with a postnatal component (0.2, 2.5, 30, or 400 mg/cg during organogenesis; noted above), pups exhibited delayed physical development at 400 mg/cg (10 times the RHD on a mg/m ² basis) and persistent reductions in body weight gain at 30 mg/kg (1 times the RHD on a mg/m ² basis) and

8.2 Labor and Delivery

Although the effect of topiramate tablets on labor and delivery in humans has not been established, the development of topiramate-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus' ability to tolerate labor [see Use in Specific Populations (8.1)].

8.3 Nursing Mothers

Limited data on 5 breastfeeding infants exposed to topiramate showed infant plasma topiramate levels equal to 10-20% of the maternal plasma level. The effects of this exposure on infants are unknown. Caution should be exercised when administered to a nursing woman.

Adjunctive Treatment for Partial Onset Epilepsy in Infants and Toddlers (1 to 24 months)

Safety and effectiveness in patients below the age of 2 years have not been establish for the adjunctive therapy treatment of partial onset setures, primary generalized ton colins setures, or setures associated with Lennox-Gastaut syndrome. In a single randomized, double-bind, placebo-controlled investigational trial, the efficacy, safety, and tolerability of topiramate or all kill and asprinke formulations as an adjunct to concurrent antibelikepic drug therapy in Infants 1 to 24 months of age with refractory topiramatic (afficient fixed doese of 5.15, and 25 molg/dg/uk) did not demonstrate efficacy compared with placebo in controlling setures.

In general, the adverse reaction profile in this population was similar to that of older pediatric patients, although results from the above controlled study and an open-label, long-term extension study in three infrants/roddlers (1 to 24 months odl) suggested some adverse reactions/toxicities (not previously observed in older pediatric patients

and adults; i.e., growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications.

These very young pediatric patients appeared to experience an increased risk for infections (any topfarmate dose 12%, placebo 0%) and of respiratory disorders (any topfarmate dose 40%, placebo 10%). The following adverse reactions were observed in at least 3% of patients on topfarmate and were 3% to 7% more frequent than in patients on placebo viral infection, incroichts, planyingks, rinnis, otts mealu, upper respiratory infinite and the state of the

Topiramate resulted in an increased incidence of patients with increased creatinine (any topiramate rose 5%, placebo 0%), BUN (any topiramate dose 3%, placebo 0%), and protein (any topiramate dose 34%, placebo 0%), and an increased incidence of decreased potassium (any topiramate dose 0%), and an increased incidence of decreased potassium (any topiramate dose 0%), and an increased incidence of decreased potassium (any topiramate dose 0%), and an increased incidence of anoteworthy increased incidence (topiramate 25 mg/kg/day 5%, placebo 0%) of a markedly abnormal lincrease (see Warnings and Precautions (5.16)). The significance of these findings is uncertain.

Topiramate treatmentation produced a dose-related increase in the percentage of patients who had a shift from normal tabaseline to high/ncreased labove the normal reference range) in total essimption of the ten of treatment. The incidence of the from 25 mg/kg/day and 11% for any topiramate dose (see Warnings and Proceedings 5.16). There was a mean dose-related increase in alkaline phosphatase. The significance of these findings is uncertain. 14%

Topiramate produced a dose-related increased incidence of treatment-emergent hyperammonemia [see Warnings and Precautions (5.10)].

Treatment with topiramate for up to 1 year was associated with reductions in Z SCORES for length, weight, and head circumference [see Warnings and Precautions (5.4) and Adverse Reactions (6)].

Adverse nearcoins (6), . In open-label, uncontrolled experience, increasing impairment of adaptive behavior was documented in behavioral testing over time in this population. There was a suggestion that this effect was dose-related. However, because of the absence of an appropriate control group, it is not known if this decrement in function was treatment-related or reflects the patient's underlying disease (e.g. patients who received higher doses may have more severe underlying disease [see Warnings and Precautions (5.6)].

In this open-label, uncontrolled study, the mortality was 37 deaths/1000 patient years. It is not possible to know whether this mortality rate is related to topiramate treatment, because the background mortality rate for a similar, significantly refractory, young pediatric population (1-24 months) with partial epilepsy is not known.

Monotherapy Treatment in Partial Onset Epilepsy in Patients <2 Years Old

Safety and effectiveness in patients below the age of 2 years have not been established for the monotherapy treatment of epilepsy. Juvenile Animal Studies

When topicarate (30, 90, or 300 mg/kg/day) was administered orally to rats during the juvenile period of development (postnatia days 12 to 50), bone growth plate thickness was reduced in males at the highest dose, which is approximately 58 times the maximum recommended pediatric dose (9 mg/kg/day) on a body surface area (mg/m ²) basis.

8.5 Geriatric Use

6.3 demark use in clinical risk, 3% of patients were over 60. No age-related differences in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Dosage adjustment may be necessary for elderly with imparied renal function (restrictinic elearance relater <70 mL/min/1.73 m °) due to reduced clearance of topiramate [see Clinical Pharmacobgy (12.3) and Dosage and Administration (2.5)].

8.6 Race and Gender Effect

Evaluation of effectiveness and safety in clinical trials has shown no race- or gender-related effects.

8.7 Renal Impairment

6.7 Kerial Impantient The clearance of topianate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m⁻²) and by 54% in severely renally impaired subjects (creatinine clearance >30 mL/min/1.73m⁻²) compared to normal renal function subjects (creatinine clearance >70 mL/min/1.73m⁻²). One-haff the usual starting and maintenance does is recommended in patients with moderate or severe renal impairment (see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].

8.8 Patients Undergoing Hemodialysis

Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than in a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to fall below that required to maintain an anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate tablets may be required.

The actual adjustment should take into account the duration of dialysis period, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed [see Dosage and Administration (2.4) and *Clinical Pharmacology* (12.3)]

8.9 Women of Childbearing Potential

8.9 Women of Childbearing Potential Data from pregnancy registris indicate that infants exposed to topiramate tablets in utero have an increased risk for cleft ip and/or cleft palate (oral clefts) *See Warnings* and *Preculitors (5.7)* and Use in *Specific Populations (8.11)*. Consider the benefits and the risks of topiramate tablets when prescribing this drug to women of childbearing potential, particularly when topiramate tablets is considered to have an condition not usually associated with permanent injury or death. Because of the risk of oral clefts to the fetus, which occur in the first trimester of pregnancy before many women know they are pregnant, all women of childbearing potential should be apprised of the potential hazard to the fetus from exposure to topiramate tablets. If the decision is made to use topiramate tablets, women who are not planning a pregnancy should use effective contracception *Bee Drug Interactions (7.31)*. Women who are planning a pregnancy should be counselled regarding the relative risks and benefits of topiramate tablets use patients (*See Patient Counseling Information (17)*).

10 OVERDOSAGE

Overdoses of topiramate tablets have been reported. Signs and symptoms included convulsions, drowsiness, speech disturbance, blurred vision, diplopia, mentation Consideration of overlaps, general distantion, stupper, hypotension, adversaria, including impaired, letharey, abnormal coordination, stupper, hypotension, adversaria agitation, dizziness and depression. The clinical consequences were not severe in most cases, but deaths have been reported after poly-drug overdoses involving Topiramate.


Topiramate overdose has resulted in severe metabolic acidosis [see Warnings and Precautions (5.4)].

A patient who ingested a dose between 96 and 110 g topiramate was admitted to a hospital with a coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days. In acute topiramate overdose, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate in vitro. Treatment should be appropriately supportive. Hemodialysis is an effective means of removing topiramate from the body

11 DESCRIPTION

Topiramate is a sulfamate-substituted monosaccharide. Topiramate tablets USP are available as 25mg, 50 mg and 100 mg circular tablets and 200 mg capsule shaped tablets for oral administration.

Topiranate USP is a white crystalline powder with a bitter taste. Topiramate USP is most soluble in akaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10.1 its freely soluble in acchene, chiorform, dimethylsultoxide, and ethanol. The solubility in water & 9.8 mg/mL, its saturated solution has a pH of 6.3. Topiramate is designated chemically as 2.34 (2016) as and pmolecular weight or 339-36. sulfamate and has the following structural formula:



Each tablet, for oral administration, contains 25 mg, 50 mg, 100 mg and 200 mg topiramate and has the following inactive ingredients: hyporomelose, lactose monohydrate, magnesium stearate, microcrystalline celulose, polyethylene glycol, polyeorbate 80, pregelatinized starch, sodium starch glycolate and tRainum dioxide addition, the 25 mg also contains FDAC Blue #2; the 50 mg and 100 mg also contair iron oxide and yelow iron oxide; and the 200 mg also contains red iron oxide. red

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The precise mechanisms by which topiramate exerts its anticonvulsant are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate efficacy for opileosy. Electrophysiological and biochemical evidence suggests that Topiramate, at pharmacological y relevant concentrations, blocks woltage-dependent sodium channes, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly bozymes II and IV.

12.2 Pharmacodynamics

Actor From Histodynamics. Topiramate has anticonvulsant activity in rat and mouse maximal electroshock seizure (MES) tests. Topiramate is only weakly effective in blocking clonic seizures induced by the GABA, a receptor antagonatic, pentylemetetrazelue. Topiramate is also effective in rodent models of epilepsy, which include tonic and absence-like seizures in the spontaneous epileptic rat (SEB) and tonic; and clonic seizures induced in rats by kinding of the amygdala or by global schemia.

12.3 Pharn acokinetics

Absorption of topiramate is rapid, with peak plasma concentrations occurring a Ausor provin or toprarmate is rapid, with peak pasma concentrations occurring approximately 2 hours following a 400 mg oral dose. The relative bioavailability topramate from the tablet formulation is about 80% compared to a solution." bioavailability of topiramate is not affected by food.

The pharmacoline of topical matter are linear with dose proportional increases in plasma concentration over the dose range studied (200 to 800 mg/day). The mean plasma elimination half-life is 21 hours after single or multiple doses. Steady-state is thus reached in about 4 days in patients with normal renaf function. Topiramate is 15% to 41% bound to human plasma proteries over the blood concentration range of 0.5 to 250 µg/mL. The fraction bound decreased as blood concentration increased.

Carbamazepine and phenytoin do not alter the binding of topiramate. Sodium valproate at 500 µg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%. Topiramate does not influence the binding of sodium valproate.

Metabolism and Excretion

Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. The metabolites are formed via hydroxylation, hydrolysis, and glucuronidation. There is evidence of renal tubular reabsorption of topiramate. In rats, given probenecit to inhibit tubular reabsorption, along with topiramate, a significant increase in renal clearance of topiramate was observed. This interaction has not been evaluated in humans. Overal, orial plasma clearance (CL/F) is approximately 20 to 30 mL/min in adults following oral administration. administration.

Special Populations

Renal Impairment

Kenai impairment The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m⁻²) and by 54% in severely renally impaired subjects (creatinine clearance - 30 mL/min/1.73m⁻²) compared to normal renal function subjects (creatinine clearance - 30 mL/min/1.73m⁻²). Since topiramate is presumed to undergo significant thubut readsorption, it is uncertain whether this experimence can be generatized to all stuations of renal impairment. It is conceivable that some forms of renal dispase - clearant for simplicant dispatch and the strain of the simplicant clearant of the simplicant simplicant conceivable that some forms of meal dispase - clearant for of molar dispatch the simplicant simplicant conceivable that conceivable that some forms of meal dispase - simplicant conceivable that conceivable that some forms of meal dispase - simplicant simplicant conceivable that conceivable that some forms of meal dispase - simplicant conceivable that conceivable that conceivable that some forms of meal dispase - simplicant conceivable that some forms of meal dispase - simplicant conceivable that some forms of meal dispase - simplicant conceivable that some forms of meal dispase - simplicant conceivable that some forms of meal dispase - simplicant conceivable that some forms of meal dispase - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conceivable that some forms of mean dispace - simplicant conc

Hemodialvsis

TrainJourgass Topiramate is cleared by hemodialysis. Using a high-efficiency, counterflow, single pass-dialysate hemodialysis procedure, topiramate dialysis clearance was 120 mL/min with blood flow through the dialyzer at 400 mL/min. This high clearance (compared to 20 to 30 mL/min total oral clearance in healthy adults) will remove a clinically significant amount of topiramate from the patient over the hemodalysis treatment period. Therefore, a supplemental dose may be required [see Dosage and Administration (2.6)].

Henatic Impairment

In hepatically impaired subjects, the clearance of topiramate may be decreased; the mechanism underlying the decrease is not well understood [see Dosage and Administration (2.7)].

Age, Gender, and Race

Age, Gender, and Race The pharmacokinetics of topiramate in elderly subjects (65 to 85 years of age, N=16) were evaluated in a controlled clinical study. The elderly subject population had reduced renal function (creatinine clearance [-20%]) compared to young adults. Following a single achieved at agrowthmatky 11 to 2 hours. Reflecting the primary rehal elimitation of topiramate, topiramate plasma and renal clearance were reduced 21% and 19%. respectively, in elderly subjects. compared to young adults. Sinilarly, topiramate half-life was longer (13%) in the elderly. Reduced topiramate clearance resulted in sliphtly higher maximum plasma concentration (23%) and AUC (25%) in elderly subjects than observed in young aduts. Topiramate clearance is decreased in the elderly only to the extent that renal function is reduced. As recommended for al platients, dosinge adjustment may be indicated in the elderly haptient when impaired renal function in the elderly patient (see Dosage and Administration (2.4) and Warnings and Precautions (5.14)]. Clearance of Tonizmate in Administration (2.4) and Warnings and Precautions (5.14). Clearance of Topiramate in adults was not affected by gender or race.

Pediatric Pharmacokinetics

Pharmacokinetics of topiramate were evaluated in patients aged 2 to <16 years. Patients received either no or a combination of other antiepleptic drugs. A population pharmacokinetic model was developed on the basis of pharmacokinetic data from relevant topiramate clinical studies. This dataset contained data from 1217 subjects including 258 petiatric patients aged 2 to <16 years (95 pediatric patients / alloy years of Patients patients).

age). Pecidiaric patients on adjunctive treatment exhibited a higher oral clearance (L/h) of topiramate compared to patients on monotherapy, presumably because of increased clearance from concomtant enzyme-inducing anticipieptic drugs, in comparison, topiramate clearance per kg is greater in peciliaric patients than in adults and in young peciliaric patients (down to 2 years) than in older peciliaric patients. Consequently, the plasma drug concentration for the same mg/kg/day dose would be lower in pediatric patiente to adults and also in younger peciliaric patients compared to older pediatric, patients. Clearance was independent of dose.

As in adults, hepatic enzyme-inducing antiepileptic drugs decrease the steady state plasma concentrations of topiramate.

Drug-Drug Interactions

Antiepileptic Drugs

Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in Table 13.

In Table 13, the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when toptramate is added. The third column (toptramate concentration) describes how the co-admixistation of a drug listed in the first column modifies the concentration of topiramate in experimental settings when topiramate was given alone.

Table 13: Summary of AED Interactions with Topiramate Tablets

AED Co-administered	AED Concentration	Topiramate Concentration			
Phenytoin	NC or 25% increase *	48% decrease			
Carbamazepine (CBZ)	NC	40% decrease			
CBZ epoxide †	NC	NE			
Valproic acid	11% decrease	14% decrease			
Phenobarbital	NC	NE			
Primidone	NC	NE			
Lamotrigine	NC at TPM doses up to 400 mg/day	13% decrease			
*= Plasma concentration increased 25% in some patients, generally those on a twice a day dosing					

regimen of phenytoin. [†]= Is not administered but is an active metabolite of carbamazepine

In addition to the pharmacokinetic interaction described in the above table, concomitant administration of valproic acid and topiramate tablets has been associated with hyperammonemis with and without encephalography and hypothermia [see Warnings and Precautions (5.10), (5.12) and Drug Interactions (7.1)]. CNS Depressants

Concomitant administration of topiramate and akohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate tablets

to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate tablets should be used with extreme caution if used in combina with alcohol and other CNS depressants [see Drug Interactions (7.2)]. used in combination

Oral Contraceptives

Oral Contraceptives In a pharmacokinetic interaction study in healthy volunteers with a concomilantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mg ethinyl estradol (EE), topiramet tablets, given in the absence of other medications at doses of 50 to200 mg/day, was not associated with statistically significant changes in mean exposure (ALC) to their component of the oral contraceptive. In another study, exposure to EE was statistically significant changes in mean exposure (ALC) to their component of the oral contraceptive. In another study, exposure to EE was statistically significant changes in mean exposure (ALC) to their component of the oral (SO mg/day to 800 mg/day) (BK), 21%, and 30%, respectively) when given as adjunctive therapy in patients taking vaprox acd. In both studies, topiramate tablets (SO mg/day to 800 mg/day) (BK) significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients taking estrogen-containing contraceptive should be asked or report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding *See Drug Interactions (7.3)*]. *Diaxin* Digoxin

In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant topiramate tablets administration. The clinical relevance of this observation has not been established.

Hvdrochlorothiazide

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmackinetics of hydrochhorothiazide (HCTZ) (25 ng q2Ah) and topiramate (96 ng q12h) when administered alone and concommantly. The results of this study indicate that topiramate $C_{\rm max}$ increased by 29% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance or this change is unknown. The addition of HCTZ to topiramate (96 or clinical significance or clinical sisometry or clinical significance or clinical significanc

Metformin

Topiramate treatment can frequently cause metabolic acidosis, a condition for which the use of metformin is contraindicated.

use of metformin is contraindicated. A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin (560 mg every 12 hr) and topiramate in plasma when metformin was given abane and when metformin and topiramate (100 mg every 12 hr) were given simultaneously. The results of this study indicated that the mean metformin C_{max} and AUC₀₋₁₂, increased by 18% and 25%, respectively, when topiramate was added. Topiramate did not affect metformin t_{max}. The clinical significance of the effect of topiramate on metormin pharmacokinetics is not known. Oral plasma clearance of topiramate and the duced when administered with metformin. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear [see Drug Interactions (7.4)].

Pioglitazone

A drug-drug interaction study conducted in healthy volunteers evaluated the steady-A drug-drug interfaction study conducted in hearry volunteers evaluated the steady-state pharmacokinetics of topicamate and polygitazone when administered alone and concomitantly. A 15% decrease in the AUC $_{\rm p, sc}$ of polygitazone with no alteration in C market was observed. This finding was not statistically dipficiant in addition, a 15% and market was observed. This finding was not statistically dipficiant in addition, a 15% and was noted as well as a 60% decrease in $C_{\rm market}$ and AUC $_{\rm p}$ and the addition of the active keto-metabolits. The clinical significance of these findings is not known. When topiramate is added to piopitazone therapy or piopitazone is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state. and

Glvburide

A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state pharmacokinetics of glyburide (5 mg/day) alone and concomtantly with topiramate (150 mg/day). There was a 22% decuction in AUC ₂₄ for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolices. 4. trans-hydroxy-glyburide during vasi reduced by 13% and 15%, and C _{max} was reduced by 13% and 25%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.

Lithium

Linuxiant in patients, the pharmacokinetics of lithium were unaffected during treatment with Topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C may and 26% for AUC) following topiramate doses up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose topiramate tablets (*Eee Turg* Interactions (7.5)). Haloperidol

The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of Topiramate (100 mg every 12 hr) in 13 healthy adults (6 males, 7 females).

Amitriptyline

There was a 12% increase in AUC and C $_{max}$ for amtriptyline (25 mg per day) in 18 normal subjects (9 males, 9 females) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in amtriptyline concentration in the presence of topiramate and any adjustments in amtriptyline does should be made according to the patient's clinical response and not on the basis of plasma levels. Sumatriotan

Multiple dosing of topiramate (100 mg every 12 hrs) in 24 healthy volunteers (14 males, 10 females) did not affect the pharmacokinetics of single-dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).

Risperidone

Reperiational When administered concomitantly with topiramate tablets at escalating doses of 100, 250, and 400 mg/day, there was a reduction in risperidone systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses of topiramate. No alterations of 9-hydroxyrisperidone levels were observed, Co-administration of topiramate. Alto mg/day doses of 00 mg/day with resperidone result of a 14% increase in $\Delta_{\rm max}$ and a 12% increase in $\Delta_{\rm L2}$ of topiramate. There were no clinically significant changes in the systemic exposure of risperidone plus 9-hydroxyrisperidone or of topiramate; therefore, this interaction is not likely to be of clinical significance.

Propranolol

Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 males, 17 females) did not affect the pharmacokinetics of propranolol folowing daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27 males, 12 females) had no effect on the exposure to topiramate, at a dose of 200 mg/day of topiramate. Dihydroergotamine

Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 males, 12 females) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamie. Similarly, a Img subcutaneous dose of dihydroergotamie did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study. Diltiazem

Co-administration of ditiazem (240 mg Cardizem CD [®]) with topiramate (150 mg/day) resulted in a 10% decrease in \mathcal{C}_{max} and a 25% decrease in \mathcal{C}_{max} and a 25% decrease in \mathcal{C}_{max} and \mathcal{L}_{max} and \mathcal{L}_{m

Venlafaxine

Multiple dosing of topiramate (150 mg/day) in healthy volunteers did not affect the pharmacokinetics of venlafaxine or O-desmethyl venlafaxine. Multiple dosing of venlafaxine (150 mg Effexor XR ®) did not affect the pharmacokinetics of topiramate. Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide, acetazolamide, or dichlorphenamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, if topiramate tablets is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of metabolic acidosis (*see Drug Interactions (7.6.*)).

Drug/Laboratory Tests Interactions There are no known interactions of topiramate with commonly used laboratory tests

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility

Carcinogenesis

Carchingueness. An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximate() ally to 1 times steady-state exposures measured in patients receiving Topiramate

onotherapy at the recommended human dose (RHD) of 400 mg, and 1.5 to 2 times Indicate appray the recommended instance (which approximately a failed by the study state topological approximate exposures in patients receiving 400 mg of topiaranate plus phenytoin. The relevance of this finding to human carchogenic risk is uncertain. No evidence of carcinogenicity was seen in rate following oral administration of topiaranate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m ² basis).

Mutagenesis

Topiramate did not demonstrate genotoxic potential when tested in a battery of *in vitro* and *in vivo* assays. Topiramate was not mutagenic in the Armes test or the *in vitro* mouse lymphoma assays, tid in cirrease unscheduled DNA synthesis in rat hepatocytes *in vitro*; and it did not increase chromosomal aberrations in human lymphocytes *in vitro*; or in at bome marrow *in vito*.

Impairment of Fertility No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m ² basis).

14 CLINICAL STUDIES

The studies described in the following sections were conducted using topiramate tablets


14.1 Monotherapy Epilepsy Controlled Trial

Patients with Partial Onset or Primary Generalized Tonic-Clonic Seizures

Adults and Pediatric Patients 10 Years of Age and Older The effectiveness of topiramate as initial monotherapy in adults and children 10 years of age and older with partial onset or primary generalized tonic-clonic seizures was established in a muticenter, randomized, double-blind, parallel-group trial.

established in a multicenter, randomized, double-blind, parallel-group trial. The trial was conducted in 487 patients diagnosed with parallel-group trial. The trial was conducted in 487 patients diagnosed with parallel-group trial. The trial was conducted in 487 patients diagnosed with parallel-group trials based with had 1 or 2 welf-document displays diagnosed with rectarging the based in open-babel fashion. Forty-nine percent of subjects had no prior AED treatment and 17% had a diagnosis of epilepsy for greater than 24 months. Any AED therapy used for temporary or emergency purposes was discontinued prior to randomization. In the double-blind phase, 470 patients were randomized to titrate up to 50 mg/day or 400 mg/day. If the target dose could not be achieved, patients were maintained on the maximum toberaid dose. Fifty-eight percent of patients achieved the maximal dose of 400 mg/day. If the darget double-blind phase. Comparison of the Kapban-no eff time to first seture during the double-blind phase. Comparison of the Kapban-Neier survival curves of time to first seture favored the toptramate 400 mg/day group over the topiramate 50 mg/day group (p=0.0002, grank test; Figure 1). The treatment effects with respect to time to first seture were consistent across various patient suburous diffiend by age, sex, geographir cagion, baseline body weight, baseline seture type, time since diagnosis, and baseline AED use. Figure 1: 1: Replan-Meer Estimates of Cumulative Rates for Time to First

Figure 1: Kaplan-Meier Estimates of Cumulative Rates for Time to First Seizure



Children 2 to <10 Years of Age

Ciniciten 2 to <10 trans of Age The conclusion that topiramate is effective as initial monotherapy in children 2 to <10 years of age with partial onset or primary generalized tonic-clonic seizures was based or a pharmacometric bridging approach using data from the controlled epilepsy trials described in labeling. This approach consisted of first showing a similar exposure response related in pediatric patients down to 2 years of age and adults when topiramate was given as adjunctive therapy. Similarity of exposure-response was also demonstructed in pediatric patients ages 6 to <16 years and adults when topiramate was given as initial monotherapy. Specific dosing in children 2 to <10 years of age was adviced from simulations utilizing plasma exposure range observed in pediatric and advice whon twich topiramate initial monotherapy (see Dosage and Administration (2.1)).

14.2 Adjunctive Therapy Epilepsy Controlled Trials

Adult Patients With Partial Onset Seizures

The effectiveness of topiramate as an adjunctive treatment for adults with partial onset setures was established in six multicenter, randomized, double-bind, placebo-controlled trips, two comparing several dosages of topiramate and placebo and four compari-single dosage with placebo, in patients with a history of partial onset setures, with or without secondarily generalized setures.

without secondarily generalized seizures. The secondarily generalized seizures, with or Patients in these studies were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topizmante tables or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a prespectified minimum number of partial onset seizures, with or without secondary generalization, during the baseline phase sectors, with or without secondary generalization, during the baseline phase and only assigned to baseline, B for 8-week baseline or 3 for 4-week baseline or week baseline or their other AEDs.

their other AEDs. Following randomization, patients began the double-blind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose wa then increased by 100 mg or 200 mg/day increments weekly or every other week until the assigned dose was reached, unless intolerance prevented furcess. In the sixth study (119), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day unitial the arrayed dose of 200 mg/day are reached. After thration, patients entered a 4, 8 or 12-week stabilization period. The numbers of patients randomized to each dose and the actual mean and median doses in the stabilization period are shown in Table 14.

Pediatric Patients Ages 2 to 16 Years with Partial Onset Seizures

The effectiveness of topiramate as an adjunctive treatment for pediatric patients ages 2 to 16 years with partial onset seizures was established in a multicenter, randomized, double-bildn, placebo-controlled trial, comparing topiramate and placebo in patients with a history of partial onset seizures, with or without secondarily generalized seizures.

A nisory or parameter secures, which a maximum of two anticelysectic drugs (AEDs) in addition to topiramate tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least six partial onset seizures, with or without secondarily generalized secures, during the baseline phase were randomly assigned to placebo or topiramate tablets in addition to their other AEDs.

Comparison and Carbon and Control C

Patients With Primary Generalized Tonic-Clonic Seizures.

The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-choic seizures in patients 2 years old and older was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing a single dosage of Topiramate and placebo.

Topramate and placebo. Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to topramate or placebo. Patients were stabilized on optimum dosages of their concomitant AEDS during an 8-week baseline phase. Patients who experienced at least three primary generalized tonic-clonic securues during the baseline phase were randomly assigned to placebo or topiramate in addition to their other AEDs. Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg/day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments very other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of my/aday was reached, unless intolerance prevented increases. After titration, patients with enony-castatt Sundrome

Patients With Lennox-Gastaut Syndrome

The effectiveness of topiramate as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome was established in a multicenter, randomized, double-bind, placebo-controlled trial comparing a single dosage of topiramate with placebo in patients

2 years of age and older.

2 years of age and older.
Patients in this study were permitted a maximum of two antispileptic drugs (AEDs) in addition to Topiramate or placebo. Patients who were experiencing at least 60 setzures per month before study entry were stabilized on optimum dosages of their concomitant AEDs during a 4-week baseline phase. Following baseline, patients were randomly assigned to placebo or topiramate tablets in addition to their other AEDs. Active drug was thrated beginning at 1 mg/kg/day for a week, the dose was then increased to 3 mg/kg/day for one week, then to 6 mg/kg/day. After thration, patients entered an 8-baseline one week, then to 6 mg/kg/day. After thration, patients entered an 8-baseline one week, then to 6 mg/kg/day. After thration, patients entered an 8-baseline one week, then to 6 mg/kg/day.

Table14:Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind, Placebo-Controlled, Add-On Trials in Adults with Partial Onset Sezures *

Target Topiramate Dosage(mg/d							mg/day)
Protoco	Stabilization Dose	Placebo †	200	400	600	800	1,000
YD	N	42	42	40	41		
	MeanDose	5.9	200	390	556		
	Median Dose	6.0	200	400	600		
YE	N	44			40	45	40
	MeanDose	9.7			544	739	796
	Median Dose	10.0			600	800	1,000
Y1	N	23		19			
	MeanDose	3.8		395			
	Median Dose	4.0		400			
Y2	N	30			28		
	MeanDose	5.7			522		
	Median Dose	6.0			600		
Y3	N	28				25	
	MeanDose	7.9				568	
	Median Dose	8.0				600	
119	N	90	157				
	MeanDose	8	200				
	Median Dose	8	200				

Doservesponse subles were not conducted to ourer indicators or pediatic partial onset seizures.
 Placebo dosages are given as the number of tablets. Placebo target dosages were as follows: Protocol Y1, 4tablets/day, Protocols YD andY2,6 tablets/day, Protocols Y3 and119, Btablets/day, Protocol YE,10tablets/day.

In all add-on trials, the reduction in seizure rate from baseline during the entire double-bilind phase was measured. The median percent reductions in seizure rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in Table 15. As described above, a global improvement in seizure severity was also assessed in the Lennov-Gastaut trials

Table 15: Efficacy Results in Double-Blind, Placebo-Controlled, Add-On Epilepsy Trials

Target Topiramate Dosage (m					ge (mg/day)			
,		Placebo				800	1, 000	≈6 mg/kg/day
	С	ompariso	ns with	n place	bo:			
Partial Onset Seizures		1						
Studies in Adults								
YD	N	45	45	45	46			
Median % Reduction		11.6	27.2 †	47.5 ‡	44.7 §			
% Responders		18	24	44 1	46 1			
YE	N	47			48	48	47	
Median % Reduction		1.7			40.8 §	41.0 §	36.0 §	
% Responders		9			40 §	41 §	36 1	
Y1	N	24		23				
Median % Reduction		1.1		40.7 #				
% Responders		8		35 1				
Y2	N	30			30			
Median % Reduction		-12.2			46.4 Þ			
% Responders		10			47 §			
Y3	N	28				28		
Median % Reduction		-20.6				24.3 §		
% Responders		0				43 5		
119 N		91	168					
Median % Reduction		20.0	44.2 [§]					
% Responders		24	45 §					
Studies in Pediatric Pa	tients							
YP	N	45						41
Median % Reduction		10.5						33.1 ¶
% Responders		20						39
Primary Generalized T Clonic ^B	onic-							
YTC	N	40						39
Median % Reduction		9.0						56.7 [¶]
% Responders		20						56§
Lennox-Gastaut Synd	Iromeà							
YL	N	49						46
Median % Reduction		-5.1						14.8 ¶
% Responders		14						28è
Improvement in Seizure Severity ð		28						52 ¶
*For Protocols YP and YT based on subject's we corresponded to mg/c *p=0.080; *p≤0.010; *p≤0.001; *p=0.050; #p=0.065; Pp≤0.005;	ight to appro	ximate a d	osage	of 6 mg	/kg pe	r day; t	(day) w hese d	ere assigned losages

 $^{*}_{p=0.005}$, $^{*}_{p>0.005}$, $^{*}_{p>0.005}$, $^{*}_{p>0.005}$, $^{*}_{p>0.005}$, $^{*}_{p>0.005}$, $^{*}_{p>0.001}$, $^{*}_{p=0.071}$, $^{*}_{p=0.0$

Subset analyses of the antiepileptic efficacy of topiramate tablets in these studies showed no differences as a function of gender, race, age, baseline seizure rate, or concomitant AED.

In clinical trials for epilepsy, daily dosages were decreased in weekly intervals by 50 to 100 mg/day in adults and over a 2- to 8-week period in children; transition was permitted to a new antiepilepitr; regime when clinically indicated.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Topiramate tablets USP

Topiramate tablets USP are available in the following strengths and colors: 100 mg, Orange colored, circular, biconvex, film-coated tablets, debossed with "124" on one side and "Cipla" on the other side and are available in

Bottles of 30 NDC 68071-3088-3 Bottles of 60 NDC 68071-3088-6

Bottles of 90 NDC 68071-3088-9

PHARMACIST: Dispense in a tight container as defined in the USP. Use child-resistant closure (as required).

16.2 Storage and Handling

Store at 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature]. Protect from moisture. Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Eye Disorders

Instruct patient taking topiramate tablets should be told to seek immediate medical attention if they experience blurred vision, visual disturbances, or periorbital pain [see Warnings and Precautions (5.1), (5.2)].

Oligohidrosis and Hyperthermia Closely monitor topiramate tablets-treated pateints, especially pediatric patients, for evidence of decreased sweating and increased body temperature, especially in hot weather. Counsel patient to contact their healthcare professionals immediately if they develop a high or persistent fever, or decreased sweating [see Warnings and Precautions (5.3)].

Metabolic Acidosis

Warn patients about the potential significant risk for metabolic acidosis that may be asymptomatic and may be associated with adverse effects on kidneys (e.g., kidney stones, nephrocakinosis), bones (e.g., ostepoporosis, ostemmakcia, and/or rickets in children), and growth (e.g., growth delay/retardation) in pediatric patients, and on th fetus (see Warnings and Precations (5.4) and Use in Specific Populations (6.1)].

Suicidal Behavior and Ideation

Coursel patients, their caregivers, and families that AEDs, including topiramate tablets, may increase the risk of suicidal thoughts and behavior, and advise of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about seri-fharm. Instruct patients to immediately report behaviors of concern to their healthcare providers [see Warnings and Precautions (5.5)].

Interference with Cognitive and Motor Performance

Warn patients mult <u>Uppinger and Institute Performance</u> Warn patients about the potential for somolence, dizziness, confusion, difficulty concentrating, or visual effects, and advise patients not to drive or operate machinery until they have gained sufficient experience on topiramate tablets to gauge whether it adversely affects their metal performance, motor performance, and/or vision [see Warnings and Precautions (5.6)].

Warnings and Precautions (5.6) I. Even when taking topirante tables other anticonvulsants, some patients with epilepsy will continue to have unpredictable setures. Therefore, advise all patients taking topiramate tablets for epilepsy to exercise appropriate caution when engaging in any activities where loss of consciousness could result in serious danger to themselves or those around them (including swimming, driving a car, climbing in high places, etc.). Some patients with refractory epilepsy will need to avoid such activities and petiter. Discuss the appropriate level of caution with patients, before patients with epilepsy engage in such activities.

Fetal Toxicity

Etai Toxicity Inform pregnant women and women of childbearing potential that use of topiramate tablets during pregnancy can cause fetal harm, including an increased risk for cleft lip and/or cleft palate (oral clefts), which occur early in pregnancy before many women know they are pregnant. There may also be risks to the fetus from chronic metabolic acidosis with use of Topiramateduring pregnancy [see Warnings and Precautions (5.7) and Use in Specific Populations (6.1), (8.9). When appropriate, course pregnant is particularly important when topiramate tablets is considered for a condition not usually associated with permanent injury or death.

Advise women of childbearing potential who are not planning a pregnancy to use

effective contraception while using topicamate tablets, keeping in mind that there is a potential for decreased contraceptive efficacy when using estrogen-containing birth control with topiramate [see Drug Interactions (7.3)].

Encourage pregnant women using (7.2); Encourage pregnant women using topiramate tables, to enrol in the North American Antiepiepic Drug (NAAED) Pregnancy Registry. The registry is collecting information about the safety of antiepiepic drugs during pregnancy. To enrol, Datients can call the toll-free number, 1-888-233-2334. Information about the North American Drug Pregnancy Registry can be found at http://www.massgeneral.org/aed/ [see Use in Specific Populations (8.1)].

Hyperammonemia and Encephalopathy

Inglear animotechia and chine china consolite day Warn patients about the possible day encophalopathy. Although hyperammonemia may be asymptomatic, cinical symptoms of hyperammonemic encophalopathy often include acute alterations in level of consciousness and/or cognitive function with lethargy or vomiting. This hyperammonemia and encophalopathy can develop with topiramate tablets treatment alone or with topiramate tablets treatment with concomitant valproic acid (VPA).

Kidney Stones

Instruct patients, particularly those with predisposing factors, to maintain an adequate fluid intake in order to minimize the risk of kidney stone formatio *n* [see Warnings and *Precautions* (5.11)].

Instructions for a Missing Dose

Instruct patients that if they miss a single dose of topiramate tablets, it should be taken as soon as possible. However, if a patient is within 6 hours of taking the next scheduled dose, tell the patient to wait until then to take the usual dose of topiramate tablets, and to skip the missed dose. Tell patients that they should not take a double dose in the event of a missed dose. Advise patients to contact their healthcare provider if they have missed more than one dose.

Manufactured by:

Cipla Ltd, Kurkumbh, In

Manufactured for:

Cipla USA, Inc. 9100 S

Dadeland Blvd., Suite 1500 Miami, Florida 33156

Revised on: 1/2015

MEDICATION GUIDE

TOPIRAMATE TABLETS, USP

Read this Medication Guide before you start taking topiramate tablets and each time you get a refill. There may be new information. This information does not take the place of taking to your healthcare provider about your medical condition or treatment. If you have any questions about topiramate tablets, tak to your healthcare provider or pharmacist.

What is the most important information I should know abo ut topi

- Topiramate tablets may cause eye problems. Serious eyroblems include: any sudden decrease in vision with or without eye pain and eye problems include: a blockage of fluid in the eye causing increased pressure in the eye (secondary angle closure glaucoma). These eye problems can lead to permanent loss of vision if not tented
- docume) closure glaucoma). These eye problems can lead to permanent loss of vision if not treated. You should cal your heakthcare provider right away if you have any new eye symptoms, including any new problems with your vision.

Topiramate tablets may cause decreased sweating and increased body temperature (fever).

People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition. Call your heathcare provider right away if you have a high fever, a fever that does not go away, or decreased sweating.

Topiramate tablets may increase the level of acid in your blood (metabolic acidosis). If left untreated, metabolic acidosis can cause britle or soft bones (osteoporosis, osteomalacia, osteopenia), kidney stones, can siow the rate of growth in children, and may possibly harm your baby if you are pregnant. Metabolic acidosis can happen with or without symptoms.

Sometimes people with metabolic acidosis will:

- Sofficiences program
 feel tired
 feel hungry (loss of appel
 feel changes in heartbeat
 have trouble thinking clearly

Note usual units of a solution of the solution of the solution of a solut

Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: • thoughts about suickle or dying new, worse, or worry you: • attempts to commit suickle • new or worse depression • new or worse anxiety

- feeling agitated or restless
- panic attacks trouble sleeping (insomnia)
- new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses
- an extreme increase in activity and talking (mania) other unusual changes in behavior or mood

Do not stop topiramate tablets without first talking to a healthcare

 Stopping topiramate tablets suddenly can cause serious problems.
 Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes

- How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or relenings. Reep al follow-up visits with your healthcare provider as scheduled. Coll your healthcare provider between visits as needed, especially if you are worried

about symptoms.

Copiramate tablets can harm your unborn baby.
 If you take topiramate tablets during pregnancy, your baby has a higher risk for birth
 defects called cleft ip and cleft palate. These defects can begin early in pregnancy,
 even before you know you are pregnant.
 Cleft lip and cleft palate may happen even in children born to women who are not
 taking any medicines and do not have other risk factors.

- There may be other medicines to treat your condition that have a lower chance of
- There may be other medicines to treat your condition that have a lower chance of birth defects.
 There may be other medicines to treat your condition that have a lower chance of birth defects.
 There may be other medicines to treat your condition that have a lower chance of birth defects.
 There may be other medicines to treat your condition that have a lower chance of the decision is made to use topiramate tablets. In the decision is made to use topiramate tablets, you should use effective birth control (contracepton) unless you are planning to become prepand. You should tak to your clotor about the best kind of birth control to use while you are taking topiramate tablets.
 Tel your healthcare provider right away if you become prepand while taking topiramate tablets. You and your healthcare provider should decide if you will continue to take topiramate tablets the birth will effects on your baby. Tak to your healthcare provider about registry is your and planmate tablets. Ne to your healthcare provider while taking topiramate tablets, tak to your healthcare provider while taking topiramate tablets. Ne to your healthcare provider about registry is topical 188-233-234. The purpose of this registry is to collect information about the safety of antiepileptic Crug drug pregnancy lengthcare; lengt

What is topiramate tablets ?

- Topiranate tablets is a prescription medicine used: to treat certain types of seizures (partial onset seizures and primary generalized tonic-clonic seizures) in adults and children 2 years and older. with other medicines to treat certain types of seizures (partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome) in adults and children 2 years and older.

What should I tell my healthcare provider before taking topiramate tablets?

Before taking topiramate tablets, tell your heathcare provider about all your medical conditions, including if you: have or have had depression, mood problems, or suicidal thoughts or behavior have kidney problems, have kidney stones, or are getting kidney dialysis have a history of metabolic acidosis (too much acid in the blood)

- flatte anison ou measure to the second secon

- have gip to ben is especially glacernal have a growth problem are on a diet high in fat and low in carbohydrates, which is called a ketogenic diet are having surgery
- are having surgery are pregnant or plan to become pregnant are pressfteeding. Topiramate tablets passes into breast milk. It is not known if the topiramate that passes into breast milk can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take topiramate tablets.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Topiramate tablets and other medicines may affect each other causing side effects.

- orner meacines may artect each orner classing side effects. Especially tell oyun healthcare provider if you take: Valproic acid (such as DEPAKENE or DEPAKOTE) Any medicines that impair or decrease your thinking, concentration, or muscle coordination Birth control pills. Topiramate tablets may make your birth control pills less effective. Tell your healthcare provider if your menstrual bleeding changes while you are taking birth control pills and topiramate tablets.
- Ask your healthcare provider if you are not sure if your medicine is listed above

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmactic each time you gate a new medicine. Do not start a new medicine without talking with your healthcare provider.

- taking with your healthcare provider.
 How ahoud 1 take top/amounte tablet?
 How ahoud 1 take top/amounte tablet?
 Your healthcare provider may change your dose. Do not change your dose without taking to your healthcare provider.
 Top/amounte tablets exactly is prescribed.
 Your healthcare provider may change your dose. Do not change your dose without taking to your healthcare provider.
 Top/amounte tablets should be swallowed whole. Do not chew the tablets. They may leave a bitter taste.
 Top/amounte tablets should be swallowed whole. Do not chew the tablets. They may leave a bitter taste.
 If you these tablets can be taken before, during, or after a meal. Drink plenty of fluids during the day. This may help prevent kidney stones while taking top/amate tablets.
 If you miss aingle dose of top/amounte tablets, take it as soon as you can. However, your usual dose of top/amate tablets, and kib the missed dose. Do not double your dose. If you have missed more than one dose, you should cal your healthcare provider.
 Do not stop taking top/amate tablets, whout taking to your healthcare provider. Stopping top/amate tablets suddenly may cause serious problems. If you may have estures
- propping topin annue: tablets suddenly may cause serious problems. If you have epilepsy and you stop taking topinamate tablets suddenly, you may have seizures that do not stop. Your healthcare provider will tell you how to stop taking topinam tablets slowly. Your healthcare provider may do blood tests while you take topiramate tablets

What should I avoid while taking topiramate tablets. What should I avoid while taking topiramate tablets? Do not drivit acbold while taking topiramate tablets. Topiramate tablets and akohol can affect each other causing side effects such as sleepiness and dizzines. Do not drive a car or operate heavy machinery unit you know how topiramate tablets affects you. Topiramate tablets can slow your thinking and motor skills, and may affect vision.

What are the possible side effects of topiramate tablets?

Topiramate tablets may cause serious side effects including: See "what is the most important information i should know about topiramate tablets?"

 High blood ammonia levels. High ammonia in the blood can affect your mental activities, slow your alertness, make you feel tired, or cause vomiting. This has happened when topiramate tablets is taken with a medicine called valproic acid happened when topiramate tablets is (DEPAKENE and DEPAKOTE).

Kidney stones. Drink plenty of fluids when taking topiramate tablets to decrease your chances of getting kidney stones.

Low body temperature. Taking topiramate tablets when you are also taking valproic acid can cause a drop in body temperature to less than 95°F, feeling tired, confusion, or coma.

Effects on thinking and alertness. Topiramate tablets may affect how you think and cause confusion, problems with concentration, attention, memory, or speech Topiramate tablets may cause depression or mood problems, tiredness, and skephess Dizziness or loss of muscle coordination.

Call your healthcare provider right away if you have any of the symptoms above. The most common side effects of topiramate tablets include:
 tingling of the arms and legs (paresthesia)
 not feeling hungry

- nausea a change in the way foods taste diarrhea
- weight loss
- upper respiratory tract infection speech problems tiredness
- dizziness -looniness/drowsir
- slow reactions difficulty with memory
- pain in the abdome
- feverabnormal vision

Tell your healthcare provider about any side effect that bothers you or that does not go

These are not all the possible side effects of topiramate tablets. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Cipla Ltd. at 1-866-604-3268

How should I store topiramate tablets • Store topiramate tablets USP at room temperature, 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature].

Keep topiramate tablets in a tightly closed container

Keep topiramate tablets dry and away from moisture. Keep topiramate tablets and all medicines out of the reach of children.

General information about topiramate tablets

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use topiramate tablets for a condition for which it was not prescribed. Do not give topiramate tablets to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about topiramate tablets. If you would like more information, talk with your heathcare provider. You can ask your pharmacits or healthcare provider for information about topiramate tablets that is written for health professionals.

For more information, call 1-866-604-3268

What are the ingredients in topiramate tablets?

Active ingredient: Topiramate USP

Active ingredient: lopramate USP Inactive ingredients: • Tablets - Tablets - contain hypromeliose, lactose monohydrate, magnesium stearate, microcrystaline celluiose, polyethylene glycol, polysorbate 80, pregelatinized starch, sodium starch glycolate and thanium dioxide. In addition, the 25 mg also contains FDCS Clau #2; the 50 mg and 100 mg also contain red iron oxide and yellow iron oxide; and the 200 mg also contains red iron oxide.

Manufactured by:

Cipla Ltd Kurkumbh, India

Manufacture for:

Cipla USA, Inc., 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156

Revised: 1/2015

This Medication Guide has been approved by the U.S. Food and Drug Administration.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL



TOPIRAMATE

Inactive Ingredier LACTOSE MONOHYDRA STARCH, PREGELATINI CELLULOSE, MICROCR SODIUM STARATH MAGNESIUM STARATH HYPROMELLOSE 2910	DRUG DRUG DRUG DRUG DRUG Active Molety Ingredient Name suggiss) (TOPINAMATE - UNIL:047204[397 Ingredient Name TE (UNIL: SV0570850) ED COMI (UNIL: 062270755)) FSTALLINE (UNIL: 06718Q0610) DATE TYPE A POTATO (UNIL: 3569370)) Tr	NDC:680 124) Basis of Stre	10	trength 0 mg	
Active Ingredient, TOPIRAMATE (UNE OHT Inactive Ingredien Lactose Monohydra Stack, predelatini Cellulose, MicRock Solumi Stack, Predelatini Solumi Stack, Predelatini Solumi Stack, Predelatini Stack, Pred	Active Moiety bgredient Name 201333) (TOPHAMATE - UNEOHT30(333) Its Ingredient Name TE (UNE: V042504050 TE (UNE: V042504753) STALLIME (UNE: 051420541) OLATE TYPE A POTATO (UNE: 3584541 (UNE: 700370430)) Tr		10	0 mg	
TOPIRAMATE (UNII: 0H7 Inactive Ingredien LACTOSE MONOHYDRA STARCH, PREGELATINI CELLULOSE, MICROCR SODIUM STARCH GLYC MAGNESIUM STEARATH HYPROMELLOSE 2910	Ingredient Name 30(333) (TOP/RAAKTE - UNIE-OHT3VIJJ333 sts Ingredient Name TE (UMIE: EVQ37G85X) TE (UMIE: EVQ37G85X) OLATE TYPE & POTATO (UMIE: 8585)3 UMIE: TOP/GRAD)) Tr		10	0 mg	
TOPIRAMATE (UNII: 0H7 Inactive Ingredien LACTOSE MONOHYDRA STARCH, PREGELATINI CELLULOSE, MICROCR SODIUM STARCH GLYC MAGNESIUM STEARATH HYPROMELLOSE 2910	Ingredient Name 30(333) (TOP/RAAKTE - UNIE-OHT3VIJJ333 sts Ingredient Name TE (UMIE: EVQ37G85X) TE (UMIE: EVQ37G85X) OLATE TYPE & POTATO (UMIE: 8585)3 UMIE: TOP/GRAD)) Tr		10	0 mg	
Inactive Ingredieu STARCH, PREGELATIWI STARCH, PREGELATIWI SODIUM STARCH GLYC MAGNESIUM STEARATH HYPROMELLOSE 2910	ING391) (TOPIRAMATE - UNIE-OH73WJJ391 ISS Ingredient Name TE (UNIE: EV05708157) (UNIE: 0023704153)) ISTALLINE (UNIE: 0P1R32061U) OLATE TYPE A POTATO (UNIE: S563)31 (UNIE: 7003704630)) Tr		10	0 mg	
Inactive Ingredieu STARCH, PREGELATIWI STARCH, PREGELATIWI SODIUM STARCH GLYC MAGNESIUM STEARATH HYPROMELLOSE 2910	Ingredient Name TE (UNI: EWQ57Q85X) EC CORN (UNI: 0822XY35)) YSTALLINE (UNI: 091832D61U) OLATE TYPE A POTATO (UNI: 5856)3/ (UNI: 70037M650)		PPIRAMATE			
ACTOSE MONOHYDRA STARCH, PREGELATINI ELLULOSE, MICROCR SODIUM STARCH GLYC MAGNESIUM STEARATE HYPROMELLOSE 2910 HYPROMELLOSE 2910	Ingredient Name TE (UNII: EWQ57Q8I5X) ZED CORN (UNII: 08232NY35J) YSTALLINE (UNII: 0P1R32D61U) OLATE TYPE A POTATO (UNII: 5856J3(: (UNII: 70097M6I30)	;2A2)		St	rength	
STARCH, PREGELATINI CELLULOSE, MICROCR SODIUM STARCH GLYC MAGNESIUM STEARATE HYPROMELLOSE 2910 HYPROMELLOSE 2910	TE (UNII: EWQ57(815X) ZED CORN (UNII: 08232NY35J) (STALLINE (UNII: 091R32D61U) OLATE TYPE A POTATO (UNII: 5856J3) : (UNII: 70097M6130)	i2A2)		St	rength	
STARCH, PREGELATINI CELLULOSE, MICROCR SODIUM STARCH GLYC MAGNESIUM STEARATE HYPROMELLOSE 2910 HYPROMELLOSE 2910	ZED CORN (UNII: 08232NY3SJ) (STALLINE (UNII: 0P1R32D61U) OLATE TYPE A POTATO (UNII: 5856j3) : (UNII: 70097M6130)	i2A2)				
CELLULOSE, MICROCR SODIUM STARCH GLYC MAGNESIUM STEARATE HYPROMELLOSE 2910 HYPROMELLOSE 2910	STALLINE (UNII: OP1R32D61U) OLATE TYPE A POTATO (UNII: 5856j30 (UNII: 70097M6130)	(2A2)				
SODIUM STARCH GLYC MAGNESIUM STEARATE HYPROMELLOSE 2910 HYPROMELLOSE 2910	OLATE TYPE A POTATO (UNII: 5856)31 (UNII: 70097M6130)	i2A2)				
MAGNESIUM STEARATE HYPROMELLOSE 2910 HYPROMELLOSE 2910	(UNII: 70097M6I30)	i2A2)				
HYPROMELLOSE 2910 HYPROMELLOSE 2910						
HYPROMELLOSE 2910	(3 MPA.S) (UNII: 0VUT3PMY82)					
TITANIUM DIOXIDE (UN	(6 MPA.S) (UNII: 0WZ 8WG20P6)					
	L 400 (UNII: B697894SGQ)					
POLYSORBATE 80 (UNII						
FERRIC OXIDE YELLOW						
Product Characte Color ora	nge	Score		no sco	re	
Shape ROI	JND (Circular, biconvex)	Size 9n			9mm	
Flavor		Imprint	Code	124;Ci	pla	
Contains						
		Marketing Start Marke				
Packaging	Package Description			Marketi		
# Item Code	Package Description	D	ate	Marketi Dat		
Item Code 1 NDC:68071- 3088-3 30 i Prod	1 BOTTLE; Type 0: Not a Combination luct 1 BOTTLE; Type 0: Not a Combination		ate			

Establishment							
Name	Address	ID/FEI	Business Operations				
NuCare Pharmaceuticals, Inc.		010632300	repack(68071-3088)				
Revised: 7/2024			NuCare Pharmaceuticals, Inc				

Revised: 7/2024